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Zusammenfassung  
Bei Patienten mit chronischer Herzinsuffizienz (CHF) korreliert der Plasmaspiegel 
von Cardiotrophin-1 (CT-1) mit dem Schweregrad der Erkrankung, wobei die 
pathophysiologischen Zusammenhänge bislang unzureichend sind. Als 
Transmitter in der Akutphase hat CT-1 eine modellierende Rolle bei 
Entzündungsreaktionen. Da es über eine Cytokinantwort die Entzündung 
hochinflammatorisch aufrechterhält, könnte bei CHF-Patienten, die mit der 
Grunderkrankung assoziierte chronische Reaktion weiterhin verstärkt und 
prolongiert werden. 
Ein wichtiger Co-Faktor bei der CHF ist der Tumornekrosefaktor α (TNF-α), der 
nachgewiesenermaßen selbst zu einer Herzinsuffizienz führen kann bzw. die 
Symptomatik der CHF weiter verschlechtert. 
Entsprechend war es Ziel der vorliegenden Arbeit, die Rolle von CT1 im Hinblick 
auf Signalwege und Cytokinproduktion in peripheren, mononukleären Blutzellen 
(PBMC) zu untersuchen. Dabei sollte die Expression von TNF-α in den PBMC als 
zugrunde liegender Singnalweg maßgeblich erforscht werden. 
Es wurden PBMC aus menschlichem Vollblut isoliert und in vitro kultiviert. Zur 
Messung der intrazellulären Signalproteine wurde ein Westernblott verwendet. 
Die mRNA der Cytokinaktivierung wurde mittels Realtime-PCR erfasst und die 
entsprechenden Proteine mit einem ELISA analysiert. 
Es zeigte sich, dass die beiden Untereinheiten (gp130/LIFR-β) des heterodimeren 
Rezeptors für CT-1 auf den PBMC exprimiert werden. Über diesen Rezeptor 
werden CT-1 vermittelt PBMC angeregt, die extrazelluläre signalregulierende 
Kinase (ERK) sowie die P38 mitogenaktivierte Proteinkinase (MAKP) und damit 
letztlich die Expression von TNF-α zu induzieren. Somit wird durch CT-1 die 
Produktion von TNF-α sowohl auf mRNA- als auch auf Proteinebene in den 
PBMC induziert. Dabei sind Monozyten jedoch keine lymphozyteren Zellen 
beteiligt. Weiterhin bewirkt CT-1 eine Translokation von dem nukleären Faktor 
kappa B (NFκB) in den Zellkern der PBMC unter Vermittlung eines Inhibitors von 
κB (IκB). Nach Zugabe von Partenolid, einem Inhibitor der NFκB-Aktivierung, wird 
CT-1 induzierte Translokation von NFκB in den Zellkern vollständig blockiert. 
 v
Gleichzeitig führt die Gabe von Fentolide zu einer Inhibition der CT-1 induzierten 
Expression von TNF-α in den PBMC. Die Zugabe des MAPK-Aktivators 
SB203580 sowie des Inhibitors der ERK-Aktivierung PD98059 zeigten keinen 
Effekt auf die Expression von TNF-α. 
Somit kann geschlussfolgert werden, dass die nukleäre Translokation von NFκB 
essentiell für die CT-1 induzierte Expression von TNF- α in den PBMC ist und die 
Aktivierung von NFκB unter Umgehung des MEK- und MAPK-Weges direkt erfolgt. 
Aufgrund der vorgestellten Experimente kann ein neuer Mechanismus der 
Aktivierung von PBMC postuliert werden, wobei erhöhte TNF-α Konzentrationen 
über den NFκB-Signalweg bei Patienten mit CHF erfolgt. Dies unterstreicht die 
Bedeutung von CT-1 bei der Pathophysiologie der CHF über die chronische 
Entzündungsreaktion hinaus. Die NFκB vermittelte TNF-α Expression in PBMC 
bietet möglicherweise einen neuen Therapieansatz für die Behandlung von 
Patienten mit chronischer Herzinsuffizienz. 
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Abstract 
Plasma cardiotrophin-1 (CT-1) levels increase with the severity of congestive 
heart failure (CHF). However, the role of CT-1 in the pathophysiology of CHF 
remains unclear. CT-1 is a strong acute-phase mediator and might play an 
important role in the regulation of inflammatory process. Since 
immune-inflammatory activation is associated with the progression of CHF, the 
possibility exits that CT-1 might play a role in modulating the immune response 
and cytokine activation in CHF, which in turn might contribute to the deterioration 
and progression of CHF.  
The purpose of this study is to elucidate the role of CT-1 on the activation 
(including signaling pathway and cytokines production) of peripheral blood 
mononuclear cells (PBMC), and further evaluate its effects on the expression of 
TNF-α in PBMC and reveal the underlying signaling pathways involved in this 
process.  
PBMC were isolated and purified from human whole blood, and cultured in vitro. 
Intracellular signaling proteins were determined by Western blotting, nuclear 
translocation of transcription factors was evaluated by electrophoretic mobility 
shift assay, mRNA level of cytokines was measured by real-time PCR, and the 
protein production of cytokines was assessed by ELISA and flow cytometry.  
This study showed that both subunits for forming the heterodimer receptor of 
gp130/LIFR-β for CT-1 action were expressed on PBMC. Via this receptor, CT-1 
activated PBMC by evoking extracellular-signal-regulated kinase (ERK) and P38 
mitogen-activated protein kinase (MAKP) signaling pathways, and promoting 
TNF-α expression. CT-1 significantly induced TNF-α production at both mRNA 
and protein levels in PBMC. Moreover, it has been shown that the subpopulation 
of monocytes but not lymphocytes were responsible for this effect. In addition 
CT-1 can induce nuclear factor kappa B (NFκB) translocation into the nucleus in 
PBMC, which was mediated by inhibitor of kappa B (IκB) degradation. 
Parthenolide (an inhibitor of NFκB activation) interrupted nuclear translocation of 
NFκB and completely inhibited the CT-1-induced TNF-α expression in PBMC, 
whereas SB203580 (an inhibitor of P38 MAPK activation) and PD98059 (an 
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inhibitor of ERK activation) had no effects on them. These results indicate that 
NFκB nuclear translocation is essential for CT-1-induced TNF-α expression in 
PBMC and that CT-1 might activate NFkB via Raf-1 directly as ‘‘skip’’ activation 
sequences but not via Raf-1/MEK/MAPKs pathway. 
These observations offer a new mechanism of activated PBMC, increased serum 
TNF-α concentration and active NFkB signaling pathway in CHF, which have 
significant implications for revealing a new mechanism of immune activation in 
CHF. Interestingly, in the present study LPS was not needed for the induction of 
TNF-α expression in PBMC. Moreover, this study may also elucidate a potential 
role of CT-1 in the pathophysiology of CHF and illustrate that heart is not only just 
a target of the inflammatory state in heart failure, but also play a role in the 
activation of inflammatory response by secreting CT-1 into the peripheral 
circulation, at least in part as a cause for initiating or promoting the inflammatory 
response in heart failure. In the light of these results, modulating CT-1 may be an 
interesting pharmacological target in the treatment of CHF. 
 
Introduction 
1  Introduction    
1.1  Cardiotrophin-1 
Cardiotrophin-1 (CT-1), a 201 amino acid protein, was originally isolated in 1995 
for its ability to induce a hypertrophic response in neonatal cardiac myocytes 
(Pennica, King et al. 1995). Amino acid sequence similarity as well as structural 
homology with the interleukin (IL) -6  family indicated that CT-1 is a member of 
this family, which includes IL-6, leukemia inhibitory factor (LIF), ciliary 
neurotrophic factor (CNTF), oncostatin M (OSM), cardiotrophin-like cytokine 
(CLC), and IL-11 (Pennica, King et al. 1995). These cytokines mediate a 
pleiotropic set of growth and differentiation activities through an unique receptor 
system, consisting of the non-signaling α-receptors (IL-6Rα, IL-11Rα, and 
CNTFRα, where R refers to receptor) and the signal transducing receptors 
(glycoprotein 130 (gp130), LIFR, and OSMR). The latter associates with janus 
kinase (JAK) and become tyrosine phosphorylated in response to cytokine 
stimulation. Each of the IL-6-type cytokines is characterized by a certain profile 
of receptor recruitment that in all cases involves at least one molecule of gp130. 
Transcripts of gp130 messenger ribonucleic acid (mRNA) are found throughout 
murine tissues (Saito, Yoshida et al. 1992), and this could explain the pleiotropic 
activities of IL-6 family cytokines, including CT-1 (Latchman 2000).  
IL-6, IL-11 and CNTF first bind specifically to their respective α-receptor subunits. 
Here, only the complex of cytokine and α-receptor efficiently recruits the 
signaling receptor subunits. Also, an α-receptor subunit has been postulated for 
CT-1 (Robledo, Fourcin et al. 1997), but since this putative receptor protein has 
not been cloned yet its existence is questionable. IL-6 and IL-11 are the only 
IL-6-type cytokines that signal via gp130 homodimers. The remaining IL-6 type 
cytokines signal via heterodimers of either gp130 and the LIFR (LIF, CNTF, CT-1 
and CLC) or gp130 and the OSMR (OSM). Human OSM has the exceptional 
capability to recruit two different receptor complexes. It forms both LIFR-gp130 
and OSMR-gp130 heterodimers. LIF and OSM directly engage their signaling 
receptor subunits without requirement for additional α-receptor subunits (Fig. 1) 
(Heinrich, Behrmann et al. 1998; Senaldi, Varnum et al. 1999). gp130 and 
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leukemia inhibitory factor receptor subunit beta (LIFR-β) is required for CT-1 
signaling, because a monoclonal anti-gp130 antibody or LIFR-β antagonist 
completely inhibits c-fos induction by CT-1. Upon stimulation with CT-1, both 
gp130 and the LIFR-β are tyrosine-phosphorylated, providing further evidence 
that CT-1 signals through the gp130/LIFR-β heterodimer (Wollert, Taga et al. 
1996).  
 
Figure 1. Receptor complexes of IL-6-type cytokines. IL-6-type cytokine receptor 
complexes signal through different combinations of the signaling receptor subunits 
gp130, LIFR and OSMR, with gp130 being used by all the family members (Heinrich, 
Behrmann et al. 2003). 
 
The signaling pathway downstream from gp130 is reported to consist of, at least, 
three distinct pathways: 1) the JAK/ signal transducer and activator of 
transcription (STAT) pathway, 2) the mitogenactivated protein kinase (MAPK) 
pathway, including the extracellular- signal-regulated kinase (ERK) -1/2, P38 
mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) 
pathway (Heinrich, Behrmann et al. 1998; Zauberman, Zipori et al. 1999; Wang, 
Robledo et al. 2000; Bode, Ludwig et al. 2001), 3) the phosphatidylinositol 3-OH 
kinase (PI3K) / protein kinase B (Akt) pathway (Kuwahara, Saito et al. 2000). 
Figure 2 shows the so far known signaling pathways of CT-1: Activation of the 
JAK/STAT pathway causes tyrosine phosphorylation of the STAT3 factor 
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(Yamauchi- Takihara 2002), resulting in its dimerization and transport to the 
nucleus where it activates its target genes (Wegenka, Buschmann et al. 1993; 
Akira, Nishio et al. 1994). The MAPK pathway is directly responsible for the 
phosphorylation and activation of nuclear factor interleukin-6 (NF-IL6), a 
transcription factor involved in cytokine signal transduction (Nakajima, Kinoshita 
et al. 1993). Finally, activation of the PI3K pathway causes the phosphorylation 
of Akt and the pro-apoptotic gene Bcl-2-associated death promoter (BAD) 
(Kuwahara, Saito et al. 2000).  
 
 
 
 
Figure 2. Schematic structure of CT-1 receptor, composed by the LIFR/gp130 
heterodimer, and the intracellular pathways activated by CT-1 (Calabrò, Limongelli 
et al. 2009). 
 
1.2  Expression and effects of CT-1 
Many scientific works have shown that CT-1 has different effects on a variety of 
tissues, such as growth of the liver, kidney, and spleen; atrophy of the thymus; 
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increase in platelet and red blood cells count (Jin, Yang et al. 1996); defence of 
the liver against proapoptotic stimuli (Marques, Belza et al. 2007); increase in 
airway smooth muscle (ASM) mass; reduction in isoprotenerol-induced ASM 
relaxation (Zheng, Zhou et al. 2004); activation of JAK/STAT and MAPK 
pathways in both preadipocytes and adipocytes; reduction in insulin stimulated 
glucose uptake (Zvonic, Hogan et al. 2004); support of survival of damaged 
motoneurones (Oppenheim, Wiese et al. 2001; Forger, Prevette et al. 2003). 
CT-1 can act not only by paracrine, but also autocrine mechanisms. Transcripts 
of CT-1 mRNA have been detected in a variety of both neonatal and adult 
tissues (Pennica, Swanson et al. 1996; Sheng, Pennica et al. 1996). In the adult 
organism, CT-1 is produced predominantly in the heart, where it is synthesized 
by both cardiomyocytes and non-cardiomyocytes and where it is secreted via 
the coronary sinus into the peripheral circulation (Asai, Saito et al. 2000). As 
demonstrated by several in vivo and in vitro experimental conditions, CT-1 has 
several different effects, providing myocardial protection, predisposing the heart 
to pathological conditions, and producing haemodynamic and endocrine effects 
(Latchman 1999). 
 
1.2.1  Effects on the heart 
Cardiac muscle cell survival plays a critical role in maintaining the normal 
function of the heart. Adult cardiac muscle cells are thought to be terminally 
differentiated. Because they have lost their proliferative capacity, an irreversible 
heart injury might result in scarring and an eventual decrease in global cardiac 
function.  
Importantly, CT-1 has been shown to be capable of promoting both the 
proliferation and the survival of either embryonic or neonatal cardiac myocytes at 
subnanomolar concentrations (Sheng, Pennica et al. 1996). Moreover, 
pre-treatment with CT-1 (1 ng/ml) has been shown to be able to protect cultured 
neonatal cardiac myocytes against subsequent exposure to either elevated 
temperature (heat shock) or ischemia/hypoxia (Stephanou, Brar et al. 1998). 
These effects were associated with the ability of CT-1 to induce enhanced levels 
of the heat shock proteins (Hsp) 70 and Hsp90 (Stephanou, Brar et al. 1998), 
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whose over-expression has been shown to protect cardiac myocytes against 
both thermal and ischemic stress (Latchman 2001; Liu, He et al. 2007; Jiao, 
Garg et al. 2008). Recent studies (Brar, Stephanou et al. 2001; Liao, Brar et al. 
2002; Lopez, Diez et al. 2005) have demonstrated, in both neonatal and adult 
cardiac cells, the cytoprotective effects of CT-1 against ischemia, when added 
both prior to and after the hypoxic stimulus, and non-ischemic death stimuli, 
such as angiotensin II (Ang II) and hydrogen peroxide (H2O2). 
Although CT-1 is expressed in the normal developing and adult heart, it was first 
isolated as a factor capable of inducing cardiac myocyte hypertrophy that is one 
of the most important adaptive responses of the heart and central feature of 
many cardiac diseases. This process, initially compensatory, causes a 
pathological transition from hypertrophy to dilation, which results in cardiac 
muscle failure at the latest stage. The original report (Pennica, King et al. 1995) 
showed that CT-1 was a dose-dependent potent inducer of myocardial 
hypertrophy, with activity being detected at concentrations of 0.1 nM or lower, 
and that it was more potent than other members of the IL-6 family in terms of 
inducing hypertrophy. In subsequent in vitro studies (Wollert, Taga et al. 1996), it 
was observed that the hypertrophy induced by CT-1 was distinct from that 
induced by α-adrenergic stimulation, both in terms of cell morphology and gene 
expression pattern. Stimulation with CT-1 leads to an increase in cardiac cell 
size that is caused by an increase in cell length without a significant change in 
cell width. CT-1-stimulated cells show the assembly of sarcomeric units in series 
(eccentric hypertrophy) rather than in parallel (concentric hypertrophy), as is 
observed with α-adrenergic stimulation. However, these studies indicate that 
CT-1 does not affect skeletal α-actin or myosin light chain-2v expression. 
Hypertrophic effects of CT-1 on the heart, were also confirmed in in vivo 
experiments (Jin, Yang et al. 1996). In fact chronic administration of CT-1 to 
mice (0.5-2.0 μg by intraperitoneal injection, twice a day for 14 days) induced a 
dose-dependent increase in both heart weight to body weight ratio, and 
ventricular weight to body weight ratio. 
Moreover, CT-1 and its receptor complex (gp130/LIFR-β) are also present in 
adult canine cardiac fibroblasts, and CT-1, dose dependently, stimulates 
deoxyribonucleic acid (DNA) and collagen synthesis with the accumulation of 
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cells in the S phase (Tsuruda, Jougasaki et al. 2002; Freed, Borowiec et al. 
2003). The primary function of adult cardiac myofibroblasts is to synthesize 
fibrillar collagens to maintain the integrity of the cardiac matrix. In addition, 
cardiac myofibroblasts play an important role in the progression of ventricular 
remodelling. 
 
1.2.2  Haemodynamic effects of CT-1 
Besides promoting cardiac growth and development, CT-1 also has effects on 
haemodynamics and cardiovascular functions. It was shown that intravenous 
administration of CT-1 (4 to 100 μg/kg) to rats caused dose-dependent systemic 
hypotension (Jin, Yang et al. 1998). Depressor response to CT-1 coincided with 
a reduction in systemic vascular resistance and resulted in a significant elevation 
in cardiac output associated with a concomitant increase in heart rate. This 
indicates that the hypotension is caused by vasodilatation. Moreover, both the 
depressor effect of CT-1 on blood pressure and the tachycardic effect were 
significantly reduced by treatment with a nitric oxide synthase inhibitor 
(NG-nitro-L-arginine methyl ester, L-NAME), suggesting that the haemodynamic 
effects of CT-1 may be mediated by nitric oxide (NO). In addition, CT-1 
administration did not result in a significant alteration in left ventricular (LV) 
maximal dP/dt (rate of rise of left ventricular pressure), a valid index of 
ventricular performance, suggesting that acute administration of CT-1 does not 
have a significant effect on ventricular contractility. On the contrary, long-term 
exposure to CT-1, as observed in human heart failure, induces contractile 
dysfunction in heart tissues reconstituted from neonatal rat cardiac myocytes 
(Zolk, Engmann et al. 2005). 
 
1.2.3  Endocrine effects of CT-1 
As previously reported, CT-1 also affects endocrine function. It stimulates atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) secretion, probably 
with a different mechanism to G protein-coupled receptor agonists that are able 
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to increase the loading condition in vivo. The biological significance of increased 
expression of ANP and BNP genes by CT-1 is not clear at present. Although 
ANP and BNP have hypotensive properties in vivo, it is unlikely that ANP and 
BNP are responsible for the decrease in blood pressure caused by CT-1 infusion, 
because the hypotensive effect of ANP and BNP is not blocked by L-NAME 
(Hamanaka, Saito et al. 2000). 
 
1.3  CT-1 and congestive heart failure 
Due to its different effects on the heart, CT-1 is considered not only as a marker 
of disease, but also it can be involved in pathological changes typical of 
congestive heart failure (CHF). CHF is a condition in which the heart's function 
as a pump to deliver oxygen rich blood to the body is inadequate to meet the 
body's needs. It is well known that neuro-humoral factors including cytokines are 
activated and play an important role in the pathophysiology of CHF. The 
mechanism of cyclic mechanical stretch-induced myocyte hypertrophy has been 
examined in isolated cultures of ventricular myocytes and cardiac nonmyocytes 
(interstitial or perivascular cells) that highlighted the possible hypertrophic effect 
of the interaction between cardiac myocytes and nonmyocytes (Harada, Saito et 
al. 1997). Both atrial and ventricular CT-1 gene expressions are increased in 
experimental congestive heart failure (Jougasaki, Tachibana et al. 2000). In a 
subsequent study (Pemberton, Raudsepp et al. 2005), it was demonstrated that 
ventricular stretch stimulates CT-1 secretion.  
Plasma CT-1 levels increase with the severity of CHF. Moreover, CT-1 
concentrations are significantly higher in explanted hearts from patients with 
end-stage heart failure than in donor hearts (Zolk, Ng et al. 2002). Plasma CT-1 
levels correlate with left ventricle mass index in patients with dilated 
cardiomyopathy (DCM) (Tsutamoto, Wada et al. 2001), which is characterized 
by volume overload, suggesting that CT-1 plays a role in left ventricular 
remodelling and/or left ventricular hypertrophy. In addition, evidence has also 
been presented that ventricular CT-1 gene activation preceded BNP gene 
activation in CHF (Jougasaki, Leskinen et al. 2003). In early left ventricular 
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dysfunction, the ventricular CT-1 gene expression was augmented, while the 
ventricular BNP gene expression was not increased. These findings raise the 
possibility that CT-1 is a biomarker for detecting early ventricular dysfunction in 
CHF as compared to BNP, which is a marker for overt CHF. Moreover, the 
additional prognostic value of CT-1 alone or combined with BNP has been 
reported in patients with CHF (Tsutamoto, Asai et al. 2007). 
 
1.4  Immune activaion in CHF 
1.4.1  Inflammation and CHF 
Heart failure involves changes in several homeostatic systems, so that the 
syndrome may be seen as a progressive multiorgan disorder which, once 
originated in the heart, spreads and affects many other extracardiac sites (Mann 
2002; Torre-Amione 2005). These pathophysiological processes include 
metabolic pathways which, although distinct, are interlinked and interact with 
each other, thus contributing to perpetuate and promote heart failure and cardiac 
remodeling, skeletal muscle cachexia, and endothelial dysfunction that 
characterize the most advanced forms of the disease. Even in the milder and 
more incipient forms of heart failure, these changes are already present and 
have been recently evaluated as potential markers for an early diagnosis and 
can, moreover, be useful as indicators of risk and prognosis (Torre-Amione 
2005).  
Immune and inflammatory changes in CHF have been recognized and evaluated 
with increasing interest in the past years. This results mainly from the 
reproduction of the changes that these mediators can produce in experimental 
models, mimicking phenotypes and different clinical patterns of the heart failure 
syndrome, notably in the cellular and subcellular processes associated with 
remodeling (Mann 2002; Torre-Amione 2005).  
By extrapolating these experimental evidences to clinical studies, high levels of 
cytokines such as tumor necrosis factor-alpha (TNF-α), IL1 and IL6 in the 
circulation and in the cardiac muscle of individuals with CHF have been 
observed to bring important prognostic information, so that these cytokines have 
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been implicated in the mechanisms of CHF progression (Levine, Kalman et al. 
1990; Ferrari, Bachetti et al. 1995; Torre-Amione, Kapadia et al. 1995; 
Torre-Amione, Kapadia et al. 1996; Hasper, Hummel et al. 1998; Adamopoulos, 
Parissis et al. 2001; Mann 2002; Torre-Amione 2005). These studies have 
generated an inexorable accumulation of evidence pointing to a progressive and 
repetitive state of immune-inflammatory activation associated with the 
progression of ventricular dysfunction, with an intense release and activation of 
cytokines, complement, autoantibodies, adhesion molecules and other 
substances in the bloodstream (Mann 2002; Torre-Amione 2005).  
 
1.4.2  Pathways for immune activation in CHF 
There are at least three well characterized pathways for immune activation in 
heart failure: ① immune activation by direct antigenic stimulation, as is seen in 
myocardial virus infection; ② secondary to cardiac injury whereby the exposure 
‘new antigens’ in myocardium is capable of triggering an immune response 
against the heart; ③ cytokine release by cardiac cells, both myocytes and 
nonmyocytes, and non-cardiac cells in response to hemodynamic deterioration. 
 
1.4.2.1  Immune activation by direct antigenic stimulation 
Immune activation by direct antigenic stimulation is best seen in two respective 
clinical settings: in patients with acute myocarditis or in patients with acute 
cardiac allograft rejection. In patients with acute myocarditis, the cardiotrophic 
virus infects the cardiac cell and triggers a variety of immune mechanisms that 
leads to the accumulation of mononuclear, B and T cells. These cells are 
capable of producing inflammatory cytokines and release toxic oxygen species 
that may affect cardiac function. In addition, activated B cells also produce 
antibodies that may be of pathological importance. This immune activation may 
repress cardiac function further inducing a vicious circle. Similarly, the 
myocardium of a heart transplant recipient that undergoes rejection is under 
direct attack by immune cells. Histological evaluation of endomyocardial 
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biopsies in the setting of cardiac rejection demonstrate the presence of 
mononuclear cells, B and T lymphocytes as well as the presence of increased 
levels of a number of proinflammatory cytokines that may lead to cardiac failure. 
Interestingly, at the histological level a biopsy from a patient with acute 
myocarditis and that of a heart transplant recipient with rejection may be 
indistinguishable. Furthermore, both conditions can produce reversible 
myocardial dysfunction. Thus, the clinical settings of acute myocarditis and 
acute cardiac rejection not only demonstrate that active inflammation is 
detrimental to cardiac function, but also that if successfully treated, may be 
potentially reversible (Fig. 3). 
 
1.4.2.2  Immune activation secondary to cardiac injury 
Immune activation secondary to cardiac injury occurs when new antigenic 
epitopes are present in the myocardium and are capable of triggering an 
immune response. For example, following a myocardial infarction there are a 
number of inflammatory cells that populate the area of infarction. There are also 
a number of autoantibodies that are present in the serum that are directed 
against cardiac specific proteins. For instance, antibodies against myosin are 
found in patients with heart failure and in experimental animals immunization 
with myosin leads to the development of myocarditis (Neu, Rose et al. 1987; 
Kohno, Takagaki et al. 2001) indicating the potential pathogenetic role of these 
antibodies (Caforio, Goldman et al. 2001; Warraich, Noutsias et al. 2002). Also, 
antibodies against the [beta]-receptor are present in patients with advanced 
nonischemic cardiomyopathy and it has been suggested that clinical 
improvements in patients that have high antibody titers are related to the 
disappearance of antibodies from the circulation (Clark, Cleman et al. 2001). In 
addition to the presence of autoantibodies, there is evidence of activation of the 
complement system (Clark, Cleman et al. 2001), increased expression of class II 
major histocompatibility molecules (Levine, Kalman et al. 1990; Torre-Amione, 
Kapadia et al. 1995) and increased expression of intracardiac cytokines (Bryant, 
Becker et al. 1998) in patients with advanced heart failure. Thus, regardless of 
the origin of initial insult, myocardial injury can induce immune activation (Fig. 3). 
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Figure 3. Pathways of immune activation in chronic heart failure. Cardiac immune 
injury is the result of activation of the immune system against virally infected cells, as 
occurs in patients with myocarditis (direct antigenic stimulation), or against the new 
expression of self-antigens that, after myocardial injury (eg, after a myocardial 
infarction), become antigenic (secondary injury). The mechanisms that follow the initial 
immune response are similar and involve the development of T cell-specific responses 
as well as antibody responses and complement activation. B = B cells; M = 
macrophage/monocyte; PFP = pore-forming (Torre-Amione 2005). 
 
1.4.2.3  Cytokine release by cardiac cells 
Recent experimental evidence suggests that myocardial cells are capable of 
producing a variety of cytokines following hemodynamic load. In a hypertensive 
murine model induced by infusion of Ang II, L-NAME and increased salt intake 
mice developed cardiac dysfunction in association with a wide array of activation 
of proinflammatory cytokines and a decrease in anti-inflammatory cytokines with 
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little or no inflammatory infiltrates, indicating that the hemodynamic load alone is 
capable of producing cardiac inflammation (Celis, Torre-Martinez et al. 2008).  
 
1.4.3  Cytokines for the immune activation in CHF 
CHF is characterized by increases in circulating proinflammatory cytokines 
(TNF-α, IL-6, IL-1β, and IL-2) and their soluble receptors or receptor antagonists 
that become more pronounced as myocardial function deteriorates (Huber-Lang, 
Younkin et al. 2002; Riedemann, Guo et al. 2002; Piagnerelli, Boudjeltia et al. 
2003). Cytokines are small molecules that interlink, amplify and propagate the 
immune response, and are involved in recruiting cells to areas of inflammation, 
stimulating cell division, proliferation and differentiation (Torre-Amione 2005). 
Cytokines, when expressed at sufficiently high concentrations, such as those 
that are observed in heart failure, are sufficient to mimic some aspects of the 
heart failure phenotype, including progressive left ventricular dysfunction, 
pulmonary edema, left ventricular remodeling, fetal gene expression, and 
cardiomyopathy (Thaik, Calderone et al. 1995; Seta, Shan et al. 1996; Kubota, 
McTiernan et al. 1997; Bozkurt, Kribbs et al. 1998). Thus, heart failure may 
progress, at least in part, as a result of the effects exerted by endogenous 
cytokines on the heart and peripheral circulation. 
These cytokines known to undergo up-regulation in patients with CHF have 
been implicated in the pathophysiology of this disease. Cytokines can affect 
myocardial function via the effects on both the myocyte contractility and the 
extracellular matrix. In addition to their effect on myocardial remodeling, 
cytokines have been shown to have direct and indirect effects on myocardial 
function (Prabhu 2004).  
Proinflammatory cytokines affect cardiac mechanical function in a temporally 
dependent, biphasic manner. The early phase is characterized by the rapid 
activation of cellular signaling mechanisms that are likely interrelated, involving 
sphingolipid, phospholipid, and constitutive nitric oxide synthetase 
(NOS)-derived NO-dependent pathways. This response may be either 
cardiostimulatory or cardiodepressant, depending on the prevailing cellular and 
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biological milieu, specifically with regard to the redox and metabolic state, the 
magnitude of extracardiac adaptive and reflex responses, and the synergistic 
and/or counter-regulatory effects of several cytokines acting in concert. The 
early response is subsequently followed by a more prolonged, delayed phase 
that uniformly demonstrates depression of both basal and stimulated contractility 
(Prabhu 2004). 
 
1.5 TNF-α and heart failure 
Cytokines are essential to propagate and magnify the immune response. 
Cytokines are involved in recruiting cells to the area of inflammation to stimulate 
cell division, proliferation, and differentiation. Accordingly, cytokines - particularly 
those that promote inflammation - are key elements of immune activation. One 
of the best characterized inflammatory molecule in CHF is TNF-α.  
 
1.5.1  TNF-α 
TNF, an endotoxin-induced serum factor that caused necrosis of tumors, was 
first identified in 1975 (Carswell, Old et al. 1975). A decade later, investigators 
isolated a protein from endotoxin-treated cells that was named cachectin 
because of its presumed role in the molecular basis of cachexia (Beutler, 
Mahoney et al. 1985; Evans, Argiles et al. 1989). The subsequent cloning of the 
genes encoding cachectin and TNF-α confirmed that these two molecules were 
identical (Pennica, Hayflick et al. 1985; Caput, Beutler et al. 1986). TNF-α is a 
trimeric 17-kDa polypeptide produced mainly by monocytes and macrophages. 
In response to a wide variety of infectious or inflammatory stimuli (e.g., 
lipopolysaccharide, viruses, fungal or parasitic antigens, IL-1, TNF-α), both 
transcription and translation of TNF precursor is increased, and large amounts of 
mature protein are rapidly released into the circulation. TNF regulates the 
expression of a variety of proteins including IL-1, IL-6, platelet derived growth 
factor, transforming growth factor-beta, as well as a group of eicosanoids and 
hormones including platelet-activating factor and adrenaline (Tracey, Vlassara et 
al. 1989). In addition, TNF-α contains a 33 nucleotide 3′-untranslated sequence 
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that shortens mRNA half-life and limits the production of large quantities of this 
peptide (Caput, Beutler et al. 1986). 
Normal myocardium does not contain TNF-α but expresses both of its receptors 
- TNF receptor type 1 and 2. However, in failing myocardium, there is increased 
expression of TNF-α, and the receptors for TNF-α are downregulated 
(Torre-Amione, Kapadia et al. 1995). Once released from the cell, TNF-α 
interacts with one of two TNF-α receptors that are expressed on many cell types 
(Torre-Amione, Bozkurt et al. 1999). The two receptors are a high-affinity 
receptor (soluble TNF receptor 1) and a low-affinity receptor (TNF receptor 2). 
The biologic activity of TNF-α can be attenuated by soluble TNF receptors. The 
cellular effects of TNF-α are highly pleiotropic. At low concentrations, TNF-α 
affects the paracrine or autocrine regulation of leukocytes and endothelial cells 
and thus serves as an important regulator of the inflammatory response. At 
higher concentrations, TNF-α production exceeds the number of TNF-α 
receptors located on the cell surface with excess TNF-α being released into the 
circulation. Once released, TNF-α exerts endocrine or exocrine effects, including 
initiation of metabolic wasting, microvascular coagulation, hypotension, and 
fever (Dinarello, Cannon et al. 1986; Feldman, Combes et al. 2000).  
 
1.5.2  TNF-α participates in the development of CHF 
The first recognition that TNF-α might participate in the development of CHF was 
reported in 1990 when circulating levels of TNF-α were demonstrated to be 
elevated in patients with end stage heart failure (Levine, Kalman et al. 1990). 
Subsequent study demonstrated a direct relationship between TNF-α levels and 
functional heart failure classification (Torre-Amione, Kapadia et al. 1996). 
Furthermore, an association between circulating levels of TNF-α and the 
prognosis in the patients with CHF were presented in the Vesnarinone trial, in 
which there is a significant overall difference in survival as a function of 
increasing TNF levels, with the worst survival in CHF patients with TNF levels 
greater than the 75th percentile (Kapadia, Torre-Amione et al. 1994; Dibbs, 
Thornby et al. 1999; Deswal, Petersen et al. 2001). In addition, direct 
relationships were identified between circulating levels of TNF-α, neurohumoral 
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activation and the degree of anemia; however, there was no relationship 
between cytokine concentrations and the degree of cachexia (Ferrari, Bachetti et 
al. 1995; MacGowan, Mann et al. 1997). TNF-α concentrations were also 
elevated in patients with heart failure due to myocarditis (Matsumori, Yamada et 
al. 1994). That the observed increases were of physiologic significance was 
demonstrated by studies in which injections of endotoxin into humans resulted in 
TNF-α elevations, depressed left ventricular function and decreases in mean 
arterial pressure (Suffredini, Fromm et al. 1989). Myocardial depression in septic 
shock is a well-defined entity. Myocardial dysfunction does not seem to be 
caused by myocardial hypoperfusion (Kumar, Haery et al. 2000) but rather by 
circulating depressant factors, cytokine TNF-α (Parrillo, Burch et al. 1985; 
Kumar, Wood et al. 2003).  
TNF-α plays a crucial role in ischemia/reperfusion injury as a part of 
postresuscitation myocardial dysfunction. It has been reported that TNF-α 
increased threefold within 15 minutes of restoration of circulation and remained 
elevated throughout the observation period (Niemann, Garner et al. 2004). A 
significant negative correlation was observed between TNF-α and left ventricular 
systolic dP/dt. TNF-α concentrations increased dramatically shortly after 
resuscitation from ventricular fibrillation and remained elevated during the early 
postresuscitation period. A significant correlation was observed between TNF-α 
concentrations and left ventricular dP/dt, suggesting an association between 
TNF-α and postresuscitation myocardial contractility. 
 
1.5.3  Mechanisms of upregulated synthesis of TNF-α in heart 
failure 
1.5.3.1  Myocardial production 
Experimental evidence of TNF-α synthesis in feline myocardium was initially 
observed in 1995 when the degree of distension of the left ventricular cavity was 
directly proportional to the local TNF-α production (Torre-Amione, Kapadia et al. 
1995; Torre-Amione, Kapadia et al. 1996). Shortly afterwards, the presence of 
mRNA and cytokine receptors were firstly observed in human myocytes isolated 
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from necropsy hearts (Ferrari, Bachetti et al. 1995). Based on these 
observations, Torre-Amione et al considered a mechanism of myocardial 
production of TNF-α to justify the elevated levels of cytokines in heart failure, 
where the diastolic wall distention associated with increased filling pressures 
would lead to a local overexpression of TNF-α, and cytokines would spillover to 
the circulation, thus contributing to the immune activation and systemic 
inflammatory status (Torre-Amione, Kapadia et al. 1995; Torre-Amione, Kapadia 
et al. 1996) (Fig. 4).  
 
 
Figure 4. Hypothesis of myocardial TNF-α production in heart failure (Candia, 
Villacorta et al. 2007). 
 
1.5.3.2  Extramyocardial production 
Hasper et al hypothesized that the inefficient vasodilator response and the 
reduced aerobic enzyme activity characteristic of the multiorgan involvement of 
heart failure would be sufficient stimuli to cause a systemic TNF-α 
overexpression, notably in skeletal muscles (Hasper, Hummel et al. 1998). 
Tissue hypoxia and free radical generation are potent stimuli for the synthesis of 
TNF-α in immunocompetent cells of the whole body (Hasper, Hummel et al. 
1998; Torre-Amione 2005); with the progression of the disease, elevated levels 
of TNF-α would worsen endothelial dysfunction, tissue hypoxia, and skeletal 
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muscle apoptosis even more, and this would serve as a stimulus for the 
systemic synthesis of TNF-α and oxidative stress, thus creating a vicious cycle 
of perpetuation of the disease and promotion of cachexia that is close to the 
model of multisystemic progression of heart failure (Tsutamoto, Hisanaga et al. 
1998; Anker and Sharma 2002). These relations are shown in Figure 5. 
 
 
Figure 5. Hypothesis of extramyocardial TNF-α production in heart failure  
(Candia, Villacorta et al. 2007). 
 
1.5.3.3  Intestinal production: the endotoxin-cytokine hypothesis 
When Anker et al. observed a concomitant TNF-α and soluble CD14 receptor 
(sCD14) elevation in the peripheral blood of patients with advanced heart failure, 
they conceived a model of cytokine activation in heart failure that would 
necessarily involve the production of endotoxins derived from intestinal bacteria 
(Anker, Egerer et al. 1997). They analyzed the peripheral levels of these 
substances in 47 patients with advanced heart failure (29 of ischemic etiology) 
and in 17 healthy controls without structural heart disease or acute/chronic 
inflammatory conditions. The levels of sCD14 were increased in patients with 
heart failure, especially in cachectic ones, and a strong correlation between the 
levels of sCD14 and of TNF-α, soluble tumour necrosis factor receptor (sTNF-R) 
1 and sTNF-R2 was observed – thus suggesting that endotoxins (ETX) were 
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involved in the immuneinflammatory activation in heart failure (Anker, Egerer et 
al. 1997). 
Thus, Anker et al. hypothesized that, in patients with heart failure, the interaction 
between CD14 receptors of immunocompetent cells and ETX released by 
gram-negative bacteria (GNB), from the gastrointestinal tract, would result in the 
activation of monocytes (Anker, Egerer et al. 1997). This interaction is actually 
documented as the most potent endogenous reaction capable of releasing 
TNF-α (Anker, Egerer et al. 1997; Niebauer, Volk et al. 1999; Torre-Amione 
2005). With the purpose of corroborating the initial hypothesis, these 
investigators later demonstrated that patients with heart failure and peripheral 
edema had higher levels of sCD14, TNF-α and ETX than those without edema, 
and the latter presented higher levels than healthy controls without heart failure 
(Niebauer, Volk et al. 1999). Moreover, after a mean 40-day treatment with 
diuretics, a significant decrease in ETX levels and a tendency of decrease in 
TNF-α levels were observed (Niebauer, Volk et al. 1999). 
Anker et al. suggested that their results supported the hypothesis that in severe 
CHF the congestion of the intestinal wall would allow a translocation and/or ETX 
release in the bloodstream (Anker, Egerer et al. 1997). After translocation there 
would be immune activation via binding of circulating ETX to CD14 receptors, 
with release of sCD14 into the bloodstream (Anker, Egerer et al. 1997), which 
can be detected in plasma (Brunkhorst, Clark et al. 1999; Niebauer, Volk et al. 
1999; Krack, Sharma et al. 2005). This mechanism of immume activation is 
called the “endotoxin-cytokine hypothesis” (Krack, Sharma et al. 2005). The 
cellular and subcellular mechanisms of this hypothesis are shown in Figures 6A 
and 6B. 
Recently, a pilot study has shown that a therapeutic potential of selective 
intestinal decontamination (SID) on the inflammatory activation in advanced 
heart failure. SID regimen with nonabsorbable antibiotics (polymyxin B and 
tobramycin for eight weeks) was able to eradicate intestinal GNB and 
significantly reduce blood and fecal levels of ETX, as well as serum levels of IL1, 
IL6 and TNF-α in patients with NYHA functional class III and IV (Conraads, 
Jorens et al. 2004).  
 18
Introduction 
 
A.   
 
 
B.  
 
Figure 6. Cellular (A) and subcellular (B) mechanisms related to the 
immuneinflammatory activation by serum ETX in heart failure. ETX - endotoxin; 
ECP - ETX carrier protein; rTL-4 - tool-like receptor 4; rCD14 - CD14 receptor; sCD14 – 
soluble portion of CD14 receptor (Candia, Villacorta et al. 2007). 
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1.5.4  Biologic effects of TNF-α on the myocardium 
Beginning with the observation that TNF-α could inhibit contractility of isolated 
hamster papillary muscles in a concentration-dependent and reversible manner 
(Finkel, Oddis et al. 1992), a series of in vivo and in vitro studies examining the 
effects of TNF-α on the myocardium were performed. First, it was demonstrated 
that the negative inotropic effects of TNF-α are virtually immediate (Eichenholz, 
Eichacker et al. 1992; Yokoyama, Vaca et al. 1993) and appear to be completely 
reversible upon removal of the cytokine. However, TNF-α does not only have 
negative inotropic effects, but it can mimic cellular and biochemical 
abnormalities that characterize the failing human heart. In addition, TNF-α 
effectively uncouples the beta-adrenergic receptors from adenylyl cyclase via an 
effect on the G inhibitory protein (Gulick, Chung et al. 1989; Chung, Gulick et al. 
1990). Furthermore, TNF-α activates metalloproteinases and inhibits the 
expression of inhibitors of metalloproteinases in vivo - effects that would be 
expected to activate extracellular matrix remodeling (Li, McTiernan et al. 1999). 
Although initial studies suggested that the negative inotropic properties of TNF-α 
were attributable to the ability of cytokines to induce NOS, subsequent 
investigations demonstrated that the induction of inducible NOS is not sufficient 
to induce contractile dysfunction in cardiac myocytes and that alterations in 
calcium homeostasis play an important role (Yokoyama, Vaca et al. 1993). 
TNF-α also provokes a hypertrophic growth response in cardiac myocytes, 
which may be an adaptive response to hemodynamic or environmental stress 
(Yokoyama, Nakano et al. 1997). Furthermore, a recent study suggested that 
the immediate negative inotropic effects of TNF-α may be mediated by 
sphingosine (Oral, Dorn et al. 1997). Finally, chronic infusion of TNF-α produces 
a reversible dilated cardiomyopathy in a rat model - without evidence of 
inflammatory infiltrate or myocyte necrosis (Bozkurt, Kribbs et al. 1998). 
 
1.6  Monocytes in the immune activation in heart failure 
Monocytes play an important role in immune defence, inflammation, and tissue 
remodelling. The function of monocytes involves phagocytosis, antigen 
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processing and presentation, and cytokine production (Swirski, Pittet et al. 2006). 
Monocytes consist of a heterogeneous multifunctional cellular population. They 
represent both the main cellular source and one of the main cellular targets of 
pre-inflammatory cytokines (Table 1) (Dutka, Elborn et al. 1993; Seta, Shan et al. 
1996; Bozkurt, Kribbs et al. 1998; Nakano, Knowlton et al. 1998; Deswal, 
Petersen et al. 2001; Lecour, Smith et al. 2002; Chung, Packer et al. 2003; 
Maack, Kartes et al. 2003; Mann, McMurray et al. 2004; Sun, Dawood et al. 
2004; Armstrong, Morrow et al. 2006; Kjekshus, Apetrei et al. 2007). However, 
their role in heart failure is not restricted to cytokine signaling. There is good 
evidence implicating monocytes in various cardiovascular disorders associated 
with heart failure.  
Under certain stimuli, circulating monocytes differentiate into macrophages. 
Macrophages are mobile, phagocytic cells specialized in removing unwanted 
cellular and extracellular debris, invading microorganisms, and other foreign 
material (Swirski, Weissleder et al. 2009). 
Monocytes are involved in atherosclerosis, the pathophysiological process 
underlying coronary artery disease and subsequently of ischaemic 
cardiomyopathy (Ross 1999). Their initially protective inflammatory response 
starts to damage the arterial wall, and dysfunctional endothelial cells (ECs) and 
macrophages release cytokines, chemokines, and growth factors, which 
promote the migration of smooth muscle cells into the intima of the arterial wall 
forming the intermediate or fibro-fatty lesion. At this stage, the lesion can contain 
multiple layers of smooth muscle cells, connective tissue, macrophages, and T 
cells (Ross 1999; Apostolakis, Vogiatzi et al. 2008). Remodelling of the vessel 
wall occurs, resulting in advanced lesion formation.  
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Table 1 Cytokines/chemokines produced by monocyte/macrophages 
in response to inflammation 
 
Cytokine Major action in relation to vascular inflammation 
TNF-α  
(Dutka, Elborn et al. 1993; Seta, Shan et 
al. 1996; Torre-Amione, Kapadia et al. 
1996; Bozkurt, Kribbs et al. 1998; 
Nakano, Knowlton et al. 1998; Deswal, 
Petersen et al. 2001; Lecour, Smith et al. 
2002; Chung, Packer et al. 2003; 
Maack, Kartes et al. 2003; Mann, 
McMurray et al. 2004; Sun, Dawood et 
al. 2004; Armstrong, Morrow et al. 2006; 
Kjekshus, Apetrei et al. 2007) 
Induces inflammation 
Induces apoptotic cell death 
Potent chemoattractant for neutrophils 
Induces chemokine/cytokine expression IL-1α/β (Apostolakis, Vogiatzi et al. 
2008) Promotes the expression of adhesion molecules 
on ECs 
Induces chemokine/cytokine production IL-6 (Seta, Shan et al. 1996; Mann 2002)
Major mediator of the acute phase response 
Neutrophil activation and chemotaxis IL-8 (Apostolakis, Vogiatzi et al. 2008) 
SMCs proliferation and migration 
Anti-inflammatory cytokine 
Down-regulates the expression of Th1 cytokinesIL-10 (Seta, Shan et al. 1996; Mann 2002) 
Inhibits NFκB activity 
Induces cell-mediated immunity 
T cell stimulating factor IL-12 (Swirski, Weissleder et al. 2009) 
Induces the production of TNF-α and INF-γ 
Induces cell-mediated immunity IL-18 (Seta, Shan et al. 1996; Mann 
2002; Apostolakis, Vogiatzi et al. 2008) Induces INF-γ production 
Activate and chemotaxis of human granulocytes MIP 1α/β (Seta, Shan et al. 1996; Mann 
2002; Apostolakis, Vogiatzi et al. 2008) Induces the synthesis and release of pro- 
inflammatory cytokines 
MCs chemotaxis and activation MCP 1 (Seta, Shan et al. 1996; Mann 
2002; Apostolakis, Vogiatzi et al. 2008) Induces SMCs accumulation and migration 
 
TNF, tumour necrosis factor-α; IL, interleukin; EC, endothelial cells; INF, interferon; MIP, 
monocyte inflammatory protein; MCP, monocyte chemoattractant protein; MC, 
monocytes; SMC, smooth muscle cells.  
 
Ischaemia-induced myocardial damage and subsequently myocardial 
remodelling and heart failure have also been associated with intense 
inflammatory activity and monocyte infiltration in the damaged tissue. In the 
early 1980s the mainstream theory indicated a rather catastrophic role of 
monocyte accumulation in the ischaemic myocardium, whereby hypoxia induces 
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necrosis in the cardiac myocytes, which subsequently stimulates the 
complement cascade and initiates an inflammatory response. Once activated, 
monocytes/macrophages produce several cytokines, chemokines, and growth 
factors, including IL-1α and -β, IL-6, TNF-α, and macrophage inflammatory 
proteins 1 α/β (Roberts, Maclean et al. 1985; Swirski, Weissleder et al. 2009). 
The theory was further supported by studies in animal models showing that the 
infarct size was reduced if blood was depleted of white cells or if lipoxygenase 
metabolism of arachidonic acid was inhibited (Ono, Matsumori et al. 1999). More 
recent studies have suggested a deteriorating effect of monocyte infiltration in 
myocardial tissue. For example, a strong association between peripheral 
monocytosis, left ventricular dysfunction, and left ventricular aneurysm formation 
after myocardial infarction is observed (Maekawa, Anzai et al. 2002). 
Consequently, inhibition of monocytes activation is a tempting therapeutic target 
in the prevention of ischaemic heart failure. 
 
Aim 
2  Aim 
Plasma CT-1 levels increase with the severity of CHF. However, the role of CT-1 
in the pathophysiology of CHF remains unclear. CT-1 is a strong acute-phase 
mediator for hepatocytes in vitro. Its activity is similar to LIF on hepatocytes, H35 
cells, and HepG2 cells that induces a dose-dependent production of several 
acute phase proteins (haptoglobin, fibrinogen, alpha1-acid glycoprotein, 
alpha2-macroglobulin), suggesting that CT-1 could play an important role in the 
regulation of the inflammatory process (Robledo, Guillet et al. 1997). As 
immuneinflammatory activation is associated with the progression of CHF, it is 
possible that CT-1 might play a role in modulating the immune response and 
cytokine activation in CHF, which in turn might contribute to the deterioration and 
progression of CHF. In addition, peripheral blood mononuclear cells (PBMC) are 
a critical component in the immune system and widely used in the research of 
inflammatory responses. It has been demonstrated that PBMC were able to 
produce TNF-α in CHF (Vonhof, Brost et al. 1998; Zhao and Xu 1999). But so far 
the mechanism responsible for TNF-α production in these cells under these 
circumstances is not fully understood.  
Given the above considerations, I hypothesized that CT-1, which is elevated in 
CHF, would activate PBMC and promote the expression of TNF-α in them. To 
test the above hypothesis, I propose to isolate and purify PBMC from human 
whole blood, and culture the cells in vitro. The first goal would be to test whether 
gp130/LIFR-β is expressed in PBMC. If gp130/LIFR-β is demonstrated to be 
expressed in them my next goal would be to elucidate whether CT-1 can activate 
PBMC by both signaling pathway and cytokines production. Further if PBMC 
demonstrated to be activated by CT-1 my future goal would be to test whether 
CT-1 can promote the expression of TNF-α in PBMC and identify the subsets of 
PBMC which is responsible for the production of TNF-α. Furthermore, the 
underlying signaling pathways responsible for CT-1 induced TNF-α production in 
PBMC will be tested.  
The present work will reveal a new mechanism of immune response and 
cytokine activation in heart failure and emphasize the role of CT-1 in the 
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pathophysiology of CHF. It will illustrate that the heart is not only just a target of 
inflammation in heart failure, but also plays a role in the activation of 
inflammatory response by secreting CT-1 into the peripheral circulation, at least 
in part as a cause for initiating or promoting the inflammatory response in heart 
failure, and therefore indicate that modulating CT-1 may be an interesting 
pharmacological target in the treatment of CHF. 
Material and Methods 
3 Material and Methods 
3.1  Reagents 
Chemicals.  All general chemicals were purchased from Carl Roth GmbH & Co., 
Karlsruhe, Merck, Darmstadt or Sigma Chemie GmbH, Deisenhofen and were of 
the highest quality.  
Antibody.  The blocking antibody against CT-1 and gp130 were purchased from 
R&D Systems (Wiesbaden, Germany). Monoclonal antibodies against inhibitor 
of kappa B (IκB), LIFR-β, STAT-1, STAT-3, ERK, P38 MAPK, JNK and the 
phosphorylated STAT-1, STAT-3, ERK, P38 MAPK, JNK were from 
BD-Pharmingen (Heidelberg, Germany), horseradish peroxidase (HRP) 
-conjugated goat anit-mouse and goat anti-rabbit IgG secondary antibodies from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Fluorescein 
Isothiocyanate (FITC) -conjugated monoclonal antibody against the surface 
antigens cluster of differentiation (CD) 3 was purchased from Coulter- 
Immunotech (Krefeld, Germany), CD4 from Caltag (Hamburg, Germany), CD8 
and CD14 from BD-Pharmingen (Heidelberg, Germany). Phycoerythrin (PE) - 
conjugated monoclonal antibodies against IL-2, IL-4, IL-5, IL-10, interferon (IFN) 
-γ and TNF-α were purchased from BD-Pharmingen (Heidelberg, Germany).  
Other Reagents.  Recombinant human CT-1 was purchased from R&D 
Systems (Wiesbaden, Germany) and dissolved according to the manufacturer´s 
instruction. Human vein endothelial cells were purchased from PromoCell 
(Heidelberg, Germany). Actinomycin D, brefeldin A, parthenolide, and PD98059 
were purchased from Sigma chemicals (Deisenhofen, Germany), SB203580 
from Upstate (Dundee, UK). PBMC separation medium Ficoll-Paque Plus from 
Amersham Bioscience (Uppsala, Sweden). RPMI 1640 from Cell Concepts 
(Umkirch, Germany). Fetal calf serum from PromoCell (Umkirch, Germany) or 
Cell Concepts (Heidelberg, Germany). Penicillin/streptomycin from Biochrom 
AG (Berlin, Germany). EpiQuikTM Nuclear Extraction KIT I were purchased from 
Epigentek (New York, USA). High Pure RNA Isolation Kit from Qiagen (Hilden, 
Germany). Reverse transcription kit from Promega (Madison, USA). Fast Start 
DNA Master SYBR Green I kit from Roche Diagnostics (Mannheim, Germany). 
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TNF-α ELISA QuantiGlo from R&D Systems (Wiesbaden, Germany). 
Electrophoretic-Mobility Shift Assay (EMSA) Kits and probes were purchased 
from Panomics (Redwood City, USA).  
 
3.2  Cell culture 
3.2.1  Isolation of human PBMC from whole blood 
3.2.1.1  Blood collection 
The PBMC were obtained exclusively from the blood of healthy volunteers. 
Venous blood (drawn in the morning from 9.00 to 11.00 h) were collected in 
EDTA tubes (1.6 mg EDTA / ml blood) (SARSTEDT AG & Co, Nümbrecht, 
Germany) from a peripheral forearm vein. 
All steps of isolation, incubation and stimulation of the cells were performed 
under sterile conditions in a laminar flow hood (HERA Safesteril Bank, Heraeus 
Instruments, Gera). 
 
3.2.1.2  Ficoll-Paque density centrifugation  
Separation medium (Ficoll-Paque Plus, Amersham Bioscience, Uppsala, 
Sweden) and sterile PBS were warmed up in room temperature. Six Leucosep 
tubes (Greiner Bio-One, Frickenhausen, Germany) were filled with 15 ml 
separation medium. After centrifugation at 1000 × g at room temperature for 30 
sec, 50ml of 1: 2 diluted anticoagulated blood sample was poured into the 
Leucosep tube (25ml per tube). After centrifugation at 1000 × g at room 
temperature for 10 min, an enriched cell fraction was located at the interface 
between plasma and separation medium as a cloudy whitish layer. The enriched 
cell fraction was harvested in another 50 ml tube. After centrifugation at 1500 
rpm at room temperature for 10 min, the supernatant was removed, then 10 ml 
of 0.83% NH4Cl was added to lyse red blood cells. Centrifugated at 1500 rpm at 
room temperature for 10 min, the supernatant was removed, and the cell pellet 
was suspended in 10 ml PBS and fresh PBS was added to an final volume of 50 
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ml. Then the cell suspension was centrifugated at 1500 rpm at room temperature 
for 10 min.  
 
3.2.1.3  Incubation and stimulation of cells 
The cells were washed three times with PBS, resuspended in RPMI 1640 
supplemented with 10% fetal calf serum (FCS), 1% penicillin, streptomycin, and 
cultivated in plastic dishes at 37°C in a humified 5% CO2 atmosphere for 24 hrs. 
Afterwards, medium was replaced by fresh medium. After 24 hours, over 90% of 
PBMC were alive tested by trypan blue exclusion. Stimulation and 
pharmacological studies were done afterwards. 
Primary cultures from human vein endothelial cells were done according to the 
manufacturer`s manual in endothelial growth medium with 2% FCS. Cells were 
grown to confluence in collagen I coated tissue culture plastic (Becton Dickinson, 
Franklin Lakes, USA). Cells were used in the second to fifth cell passages. 
All stimulants, inhibitors and media were without endotoxin levels according to 
the manufacturers’ instructions. 
Pharmacological agents, dissolved in fresh medium, were added to the cells for 
defined time intervals and concentrations. As a control, fresh medium was 
added to the cells. 
Approval of this study was given by the Ethics Committee of the 
Friedrich-Schiller-University, Jena, and subjects gave their written informed 
consent according to University guidelines. 
 
3.3  Preparation of protein probes and nuclear protein extracts 
3.3.1  Protein probes 
Depending of the application, medium was removed and 2× laemmli buffer was 
added (160 mM Tris.HCl pH 6.8, 4% SDS, 16% glycerol, and 0.005% 
bromophenol blue). Afterwards the cells were scraped and transferred to a 1.5 
ml reaction tube and the genomic DNA was sonified (Branson cell disruptor B15, 
 28
Material and Methods 
output 6) to reduce viscosity. Before loading the samples, 100 mM dithiothreitol 
(DTT) was added and proteins was denatured by heating for 3 min at 95°C. 
 
3.3.2  Nuclear protein extraction   
Nuclear extracts were achieved by the EpiQuikTM Nuclear Extraction KIT I 
according to the manufacturer’s manual. Briefly, cells were grown to 70-80% 
confluence on a culture plate (about 2-5 × 106 cells for a 100 mm plate). The 
growth medium was removed, cells were washed twice with PBS and then PBS 
was removed. The cells were added with 1 ml of fresh PBS per 20 cm2 area, and 
scraped into a 15 ml conical tube. After centrifugation at 1000 rpm for 5 min, the 
supernatant was discarded, and the cell pellet was re-suspended in 100 μl of 
diluted NE1 (10% NE1, 90% H2O, 0.1% DTT and 0.1% PIC) per 106 cells and 
transferred to a micro centrifuge vial. After incubation on ice for 10 min, the vial 
was vortexed vigorously for 10 sec and centrifuged for 1 min at 12,000 rpm. The 
cytoplasmic extract was carefully removed from the nuclear pellet. Twenty μl of 
NE2 (containing 0.1% DTT and 0.1% PIC) was added to the nuclear pellet. The 
extract was incubated on ice for 15 min with vortex (5 sec) every 3 min. The 
extract was sonicated 3 times, each 10 sec, to increase nuclear protein 
extraction. After centrifugation at 14,000 rpm at 4°C for 10 min, the supernatant 
was transferred into a new microcentrifuge vial. Protein concentration of the 
nuclear extract was measured, and then the nuclear extract was used 
immediately or aliquoted and freezed at -80°C until further use.  
 
3.4  Western blot analysis 
3.4.1  Separation of proteins by polyacrylamide gel electrophoresis 
(PAGE) 
Unless otherwise indicated for most applications a polyacrylamide separating 
gel of 10-12% was made and a 5% stacking gel. Reagents for the stacking gel 
were 8.3 ml of acrylamide/bis-acrylamide (30:0.8) 6.25 ml of 1.5 M Tris-HCl pH 
8.8, 0.124 ml of 20% sodium dodecyl sulfate (SDS), an 10.05 ml of H2O (for a 
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12% separating gel, the amount of acrylamide/bis-acrylamide added was 10 ml 
and the H2O reduced accordingly to give the same end volume). To the mixture 
was added 250 μl of 10% ammonium persulphate (APS) and the reaction 
initiated with 20 μl of tetramethylethylenediamine (TEMED). The gel mix was 
poured between two glass plates with spacers between and allowed to 
polymerize. Upon completion, a stacking gel was poured on top. This was made 
up of 1.7 ml of acrylamide/bis-acrylamide, 2.5 ml of 0.5 M Tris-HCl pH 6.8, 50 ml 
of 20% SDS, 5.65 ml of H2O, 100 μl of 10% APS and 7.5 μl of TEMED. The gel 
was then run in 1 laemmli-running buffer (25 mM Tris-HCl pH 8.3, 0.2 M glycine 
and 0.1% SDS) until the desired distance had been reached. 
 
3.4.2  Immunoblotting 
After gel electrophoresis proteins were transferred to Immobilon membranes 
(Millipore Corporation). The blots were incubated in blocking buffer, 10% 
skimmed milk, 0.1%Tween in 10 mM Tris pH 7.6, 100 mM NaCl (TBS) for 1 hour 
at room temperature. Incubation with primary antibodies was in blocking buffer 
(for phopho specific antibodies 5% bovine serum albumin (BSA), 0.1% Tween in 
TBS) for 1 hour room temperature (for phosphospecific antibodies overnight 
4°C). Washed in TBS 0.1% Tween 3 times, each 10 min. Incubation with 
peroxidase conjugated secondary antibodies was in blocking buffer for 1 hour 
room temperature. Washed in TBS 0.1% Tween 3 times, each 10 min. Blots 
were developed using enhanced chemiluminescence system (Amersham, Little 
Chalford, England) and visualized with autoradiography film (Fuji Photo Film Co. 
Ltd). 
 
3.5  Isolation of total ribonucleic acid (RNA) from cultured cells 
Total RNA from cultivated PBMC was extracted according to the protocol of High 
Pure RNA Isolation Kit. Briefly, the growth medium was removed and cells were 
resuspended with 200 µl PBS and then added 400 µl Lysis/-Binding Buffer 
(green cap) and vortexed for 15 sec. Sample was pipeted into the upper 
reservoir of the Filter Tube (max. 700 µl). After centrifugation of the tube 
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assembly at 8,000 × g for 15 sec, the Filter Tube was removed from the 
Collection Tube. The flowthrough liquid was discard, and the Filter Tube was 
again combined with the used Collection Tube. One hundred µl mixture per 
sample (90 µl deoxyribonuclease (DNase) Incubation Buffe and 10 µl DNase I) 
was pipeted on the glass filter fleece in the upper reservoir of the filter tube. After 
incubation for 15 min at 15 to 25°C, 500 µl Wash Buffer I was added to the upper 
reservoir of the Filter Tube assembly and centrifuged at 8,000 × g for 15 sec. 
The flowthrough was discarded and the Filter Tube was again combined with the 
used Collection Tube. Five hundred µl Wash Buffer II was added to the upper 
reservoir of the Filter Tube assembly and centrifuged at 8,000 × g for 15 sec. 
The flowthrough was discarded and the Filter Tube was again combined with the 
used Collection Tube. Two hundred µl Wash Buffer II was added to the upper 
reservoir of the Filter Tube assembly and centrifuged at maximum speed 
(approx. 13,000 × g) for 2 min to remove any residual Wash Buffer. The 
Collection Tube was discarded and then the Filter Tube was inserted into a 
clean, sterile 1.5 ml microcentrifuge tube. Fifty to one hundred µl Elution Buffer 
was added to the upper reservoir of the Filter Tube. The tube assembly was 
centrifuged at 8,000 × g for 1 min. Then the microcentrifuge tube contained the 
eluted RNA. The eluted RNA was used directly in reverse transcription 
polymerase chain reaction (RT-PCR) or stored at -80°C for later analysis. 
 
3.6  Reverse transcription from RNA into complementary 
deoxyribonucleic acid (cDNA) 
One µg of total RNA was reversely transcribed into cDNA in a volume of 20 µl 
with avian myeloma leukaemia virus (AMV) reverse transcriptase and oligo dT 
primers (Promega, Madison, USA) according to the manufacturer`s manual. 
Briefly, 1 μg of 1.2kb Kanamycin Positive Control RNA, poly(A)+ mRNA or total 
RNA was placed in a microcentrifuge tube, and incubated at 70°C for 10 min. 
After centrifugation briefly in a microcentrifuge,the tube was placed on ice. A 20 
μl reaction was prepared by adding the following reagents: 4 μl of 25 mM MgCl2, 
2 μl of reverse transcription 10X Buffer, 2 μl of 10 mM dNTP mixture, 0.5 μl of 
recombinant RNasin® ribonuclease inhibitor, 15 U AMV reverse transcriptase 
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(High Conc.), 0.5 μg Oligo(dT)15 primer, and nuclease-free water to a final 
volume of 20 μl. The reaction was incubated at 42°C for 15 min and heated at 
95°C for 5 min, and then incubated at 0-5°C for 5 min. 
 
3.7  Real-time PCR  
3.7.1  Principle of the assay 
Generation of PCR products can be detected by measurement of the SYBR 
Green I fluorescence signal. SYBR Green I intercalates into the DNA double 
helix. In solution, the unbound SYBR Green I dye exhibits very little fluorescence; 
however, fluorescence (wave length, 530nm) is greatly enhanced upon 
DNA-binding. Therefore, during PCR, the increase in SYBR Green I 
fluorescence is directly proportional to the amount of double-stranded DNA 
generated. 
As SYBR Green I dye is very stable (only 6% of the activity is lost during 30 
amplification cycles) and the LightCycler® Instruments’ optical filter set matches 
the wave lengths of excitation and emission, it is the reagent of choice when 
measuring total DNA. 
 
3.7.2  Assay procedure 
Real-time PCR measurement of TNF-α cDNA was performed with the Light 
Cycler Instrument using the Fast Start DNA Master SYBR Green I kit. For 
verification of the correct amplification product, PCR products were analyzed on 
a 2% agarose gel stained with ethidium bromide. The specific primer for human 
TNF-α was purchased from R&D Systems. The amplification program for TNF-α 
consisted of 1 cycle of 94°C with a 4 min hold followed by 40 cycles of 95°C with 
a 45 sec hold, 59°C annealing temperature with a 45 sec hold and 72°C with a 
45 sec hold. The specific primer pair for glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was: sense primer 5´ GGG AAG GTG AAG GTC GG 
3´, antisense primer 5´ TGG ACT CCA CGA CGT ACT CAG 3´. The 
amplification program for GAPDH consisted of 1 cycle of 95°C with a 30 sec hold 
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followed by 30 cycles of 95°C with a 5 sec hold, 59°C annealing temperature 
with a 10 sec hold and 72°C with a 20 sec hold. Each reaction (20 µl) contained 
2 µl cDNA, 2.5 mM MgCl2, 1 pmol of each primer and 2 µl of Fast Starter Mix 
(containing buffer, dNTPs, Sybr Green dye and Taq polymerase). Amplification 
was followed by melting curve analysis to verify the correctness of the amplicon. 
A negative control without cDNA was run with every PCR to assess the 
specificity of the reaction. Analysis of data was performed using Light Cycler 
software version 3.5. PCR efficiency was determined by analysing a dilution 
series of cDNA (external standard curve). The identity of the PCR product was 
confirmed by comparing its melting temperature (Tm) with the Tm of amplicons 
from standards or positive controls. GAPDH was analyzed in parallel to each 
PCR and the resulting GAPDH values were used as standards for presentation 
of TNF-α transcripts. 
 
3.8  TNF-α enzyme-linked immunosorbent assay (ELISA) 
Cultured PBMC were treated with different concentrations of CT-1 for various 
time periodes. TNF-α concentration in the culture supernatants was determined 
by ELISA according to the manufacturer´s instructions.  
 
3.8.1  Principle of TNF-α ELISA assay 
This assay employs the quantitative sandwich enzyme immunoassay technique. 
A monoclonal antibody specific for TNF-α has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any TNF-α present is 
bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for TNF-α is added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, 
an enhanced luminol/peroxide substrate solution is added to the wells and light 
is produced in proportion to the amount of TNF-α bound in the initial step. A 
microplate luminometer is used to measure the intensity of the light emitted. 
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3.8.2  Assay procedure 
 Sample collection and storage 
Cell culture supernates were collected and particulates were removed by 
centrifugation. Then the samples were assayed immediately or aliquoted 
and stored at -20°C. 
 Reagent preparation 
- Wash Buffer - 100 ml of Wash Buffer Concentrate was diluted into 
deionized or distilled water to prepare 1000 ml of Wash Buffer;  
- Working Glo Reagent –1 part Glo Reagent A (4 ml) and 2 parts Glo 
Reagent B (8 ml) were mixed together 15 minutes to 4 hours before use. It 
was stored in a capped plastic container, protected from light. One hundred 
μl of the resultant mixture is required per well; 
- Calibrator Diluent RD5P (1×) - Twenty ml of Calibrator Diluent RD5P (5×) 
was diluted into 80 ml of deionized or distilled water to yield 100 ml of 
Calibrator Diluent RD5P (1×); 
- Standard - Reconstitute Standard with 0.5 ml of deionized or distilled water. 
This reconstitution produces a stock solution of 70,000 pg/ml. The standard 
was gently agitated for a minimum of 15 min prior to making dilutions. Nine 
hundred μl of Calibrator Diluent RD5P (1×) was pipeted into the 7000 pg/ml 
tube. Eight hundred μl of the appropriate Calibrator Diluent was pipeted into 
the remaining tubes. The stock solution was used to produce a 5-fold 
dilution series. The 7000 pg/ml standard serves as the high standard. The 
appropriate Calibrator Diluent serves as the zero standard (0 pg/ml); 
 Excess microplate strips were removed from the plate frame, returned to the 
foil pouch containing the desiccant pack, and resealed; 
 One hundred μl of Assay Diluent RD1-27 was added to each well. Then, 100 
μl of Standard, sample, or control was added per well. Covered with the 
adhesive strip provided. The assay was incubated for 3 hrs at room 
temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 500 
± 50 rpm. A plate layout was provided to record standards and samples 
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assayed. Each well was aspirated and washed by filling each well with wash 
buffer (400 μl) using a manifold dispense, repeating the process three times 
for a total of four washes. After the last wash, any remaining wash buffer 
was removed by decanting. The plate was inverted and blotted against clean 
paper towels. Two hundred μl of human TNF-α conjugate was added to 
each well. The plate was covered with a new adhesive strip and incubated 
for 2 hrs at room temperature on the shaker. Repeated the aspiration/wash 
process as before four times. Then, 100 μl of Working Glo Reagent was 
added to each well and the plate was incubated for 5-20 min at room 
temperature on the benchtop by protecting from light. The relative light unit 
of each well was determined using a luminometer set with the following 
parameters; 1.0 min. lag time; 0.5 sec/well read time; summation mode; auto 
gain on. 
 
3.9  Electrophoretic mobility shift assay (EMSA) 
3.9.1  Principle of EMSA 
Panomics Electrophoretic-Mobility Shift Assay (EMSA) Kits are useful tools for 
identifying proteins that interact with DNA. This rapid technique is based on the 
separation of free DNA from protein/DNA complexes due to the differences in 
their electrophoretic mobility in native (non-denaturing) polyacrylamide gels. 
When a protein binds specifically to a labeled double stranded deoxyribonucleic 
acid (dsDNA) sequence, it migrates slower than non-bound dsDNA in a 
polyacrylamide gel, thus resulting in discrete bands corresponding to the 
individual protein/DNA complex. A typical EMSA experiment is performed by 
incubating a biotin-labeled transcription factor (TF) Probe with treated and 
untreated nuclear extracts. The protein/DNA complexes are separated on a 
non-denaturing polyacrylamide gel. The gel is transferred to a nylon membrane 
and detected using strepatvidin-HRP and a chemiluminescent substrate. The 
shifted bands corresponding to the protein/DNA complexes are visualized 
relative to the unbound dsDNA. The bands are visualized after exposure to film 
or chemiluminescent-imaging system. 
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3.9.2  Assay procedure 
 Preparing samples:  
A 10 μl reaction was prepared by adding the following reagents in a sterile 
0.5 ml microcentrifuge tube: 5 µg of nuclear extract, 2 µl of 5x binding buffer, 
1 µl of I M Poly d (I-C), and distilled water to a final volume of 7 μl for cold 
probe and 9μl for probe. After 5 min incubation at room temperature, 1µl of 
TF probe and 2 µl of cold TF probe was added to the reaction of cold probe, 
and 1µl of TF probe was to the reaction of cold probe. Both reactions have a 
final volume of 10 μl. Then the reactions were incubated at 15-20°C for 30 
min. 
 Gel preparation, loading and running: 
Reagents for the 6% polyacrylamide gel were 1 ml of 10xTBE, 4 ml of 30% 
Acrylamide/Bis, 625 µl of 80% Glycerol, 14.375 ml of dH2O, 300 µl of 10% 
APS, and 20 µl of TEMED. The gel mix was poured between two glass plates 
with spacers between and allowed to polymerize. The gel was run in chilled 
0.5× TBE for 10 min in ice bath at 120V before loading samples into gel. 
Samples were mixed with 1 µl of Loading Dye. Ten µl of sample pre lane was 
loaded. The gel was run in ice bath at 120 V until the dye reaches 2.5 cm 
from the bottom of the gel (about 50-55 min).  
 Transfer:  
Standard “wet-transfer” electroblotting procedures were performed as below. 
Nylon membrane (7 × 9 cm) was presoaked in 0.5× TBE. The gel was 
sandwiched with the presoaked membrane and two sheets of presoaked 
Whatmann paper (8 × 10 cm) on each side. The sandwich was placed in an 
electroblotting device, filled tank with 0.5× TBE, and transferred for 30-45 min 
at 300 mA at room temperature. 
 Immobilization of bound oligos: 
After transfer, the membrane was removed and baked for 1 hour at 80°C in a 
dry oven, and then transferred to a UV crosslinker oven for 3 min. 
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 Detection. 
The membrane was blocked by incubating at room temperature with 20 ml of 
1× blocking buffer for 15 min with gentle shaking. One ml of the 1× blocking 
buffer was removed from the blot container to a new eppi tube, added 20 ul of 
Streptavidin-HRP conjugate, vortexed and transferred back into the 1× 
blocking buffer. After shake at room temperature for another 15 min, the 
diluted streptavidin-HPR solution was decanted. The membrane was washed 
3 times with 20 ml of 1× wash buffer, each 8 min. Then it was added with 20 
ml of 1× detection buffer and inculated at room temperature for 5 min. Each 
membrane was placed on a plastic sheet. Two ml of mixed substrate solution 
(containing 200 ul of Solution I, 200 ul of Solution II, and 1.6 ml of Solution III) 
was pipeted onto each membrane, and a second plastic sheet was overlaid 
on it. After incubation at room temperature for 5 min, the membranes was 
exposed by using either Hyperfilm ECL (2-10 min) or a chemiluminescent 
imaging system (Fujifilm LAS-3000 Imager, Fuji Photo Film Co., Ltd., Tokyo, 
Japan ) (12-15 min). 
        
3.10  Immunofluorescent flow cytometric analysis of cytokine 
production 
3.10.1  Principle of flow cytometry 
In flow cytometry, a beam of laser light of a single wavelength is directed onto a 
hydrodynamically-focused stream of liquid. A number of detectors are aimed at 
the point where the stream passes through the light beam: one in line with the 
light beam (Forward Scatter or FSC) and several perpendicular to it (Side 
Scatter or SSC) and one or more fluorescent detectors.  
The analysis based on the specific interaction of antigen with (monoclonal) 
antibodies, which are conjugated to fluorescent dyes. During the analysis the 
suspended cells are hydrodynamical focused and pass, like a string of pearls, 
the focused laser beam. Each suspended cell passing through the beam 
scatters the ray, and fluorescent chemicals found in the cell or attached to the 
cell may be excited into emitting light at a longer wavelength than the light 
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source. This combination of scattered and fluorescent light is picked up by the 
detectors, and, by analysing fluctuations in brightness at each detector (one for 
each fluorescent emission peak), it is then possible to derive various types of 
information about the physical and chemical structure of each individual cell. 
FSC correlates with the cell volume and SSC depends on the inner complexity of 
the cell (i.e., shape of the nucleus, the amount and type of cytoplasmic granules 
or the membrane roughness). (Fig. 7). 
 
 
 
Figure 7. Schematic diagram of flow cytometry. The liquid system drives the 
analyzed cell from the sample tube (sample) through the laser beam. The sample beam 
is pulled apart by a sheath fluid (fluid envelope) to a very thin thread of liquid. The light 
scattered by the cell in the direction of the laser is detected by the FSC detector 
(forward scatter), the side scattered light (SSC, side scatter) at right angle to the laser 
beam passing through a lens system, different color filters and beam splitters is 
detected by the various detectors. The signals from the photomultiplier are amplified, 
and can be evaluated and displayed by a computer. 
 38
Material and Methods 
3.10.2  Assay procedure 
For intracellular staining peripheral blood was collected in lithium-heparin tubes. 
100 µl of blood was added to RPMI-1640 medium including brefeldin A (final 
concentration: 1 µg/ml) and incubated for 6 hours at 37°C. Then, erythrocytes 
were lysed by NH4Cl. After washing with PBS/2% FCS cells were stained with 
FITC-conjugated monoclonal antibodies against the surface antigens CD3, CD4, 
CD8 and CD14 (15 min, room temperature), followed, after a washing step, by 
fixation with 100 µl 2% paraformaldehyde for 10 min at room temperature. After 
a wash the cells were incubated in 100 µl permeabilisation solution (0.1% 
saponin and 0.1% NaN3 in PBS) together with 1 µl directly PE-conjugated 
anti-TNF-α, IL-2, IL-4, IL-5, IL-10, or IFN-γ antibodies for 15 min at room 
temperature. Followed by a wash with permeabilisation solution the cells were 
resuspended in PBS/2% FCS and fluorescence intensity was analyzed by flow 
cytometry (FACSCalibur, Becton-Dickinson, Heidelberg, Germany). For analysis 
regions were defined by forward scatter and side scatter as well as CD3+/CD4+- 
or CD3+/CD8+- lymphocyte and CD14+- monocyte populations. 
Cells incubated with PE stained non-specific IgG1 antibodies were analyzed in 
parallel to each measured approaches and measured as a negative control. A 
threshold was defined to discriminate the background fluorescence of the cells. 
Cells with a fluorescent signal that was below this threshold were considered 
negative, whereas cells with a fluorescent signal that was above this threshold 
were classified as positive or specifically stained. Ca. 1% to 2% of cells in the 
negative control were false positive. By subtracting this value from each 
measurement, the specifically stained cells or the proportion of cells expressing 
a defined protein are determined. The measurement was performed by using the 
software CellQuest (Becton Dickinson, Heidelberg, Germany) on a Macintosh 
computer. Three hundred cells were measured per second and about 5000 cells 
were analyzed. 
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3.11  Statistical analysis 
Because the amount of the cytokines produced was different in each experiment, 
the effects on TNF-α production were normalized to unstimulated cells, which 
were set as one. Data were analysed by non-parametric methods when the 
measured variables were not normally distributed. Comparisons between groups 
were made with the Wilcoxon test. All values are reported as means ± SEM. 
Probability values of <0.05 were considered statistically significant. All data 
analyses were performed with commercially available statistical analysis 
software packages (SPSS 11.5; SPSS, Chicago, IL). 
Results 
4 Results 
4.1  gp130 and LIFR-β are co-expressed in PBMC 
To determine whether gp130/LIFR-β is expressed in PBMC, I isolated and 
purified PBMC from whole blood from healthy volunteers, and cultured the 
PBMC in vitro for 24 hrs, and then tested gp130 and LIFR-β levels by Western 
blot analysis. The expression of CT-1 receptor subunits gp130 and LIFR are 
both detectable in PBMC (Fig. 8). The signal intensity of gp 130 is much stronger 
than that of LIFR-β. But never the less, a detectable signal for LIFR-β was 
obtained. More over, the application of CT-1 to the cells did not alter the 
expression of gp130 and LIFR-β.  
 
          
Figure 8. Representative expression of gp130 and LIF-β receptor in PBMC. PBMC 
were plated on poly-l-lysine coated 100 mm dishes in RPMI 1640 + 10% FCS at 
densities of 10.000 cells/cm2. After 24 hrs, cells were lysed and proteins were 
transferred to a 10% SDS-PAGE gel. Gp130 and LIF-β receptor expression was 
assayed by Western blotting using anit-gp130 and anti-LIFR-β antibodies showing a 
gp130 band at 60kDa and a LIFR-β band at 110kDa. Twenty-five μg of total protein was 
loaded per each lane. Actin served as loading control. 
 
4.2  CT-1 activates PBMC 
Activated PBMC are characterized by increased expression of certain cytokines 
or mediators of inflammation. It has been previously reported that STAT-1, 
STAT-3, ERK, P38 MAPK and JNK signaling pathways were evoked by various 
cytokines in PBMC (Dogusan, Hooghe et al. 2001; Sanchez-Margalet and 
Martin-Romero 2001; Zimmerer, Lehman et al. 2008; Broide, Scapa et al. 2009; 
Kim, Goo et al. 2009). However, the potent signaling pathways and cytokines or 
mediators involved in the CT-1 stimulation in PBMC are still unknown. To 
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address this problem, I stimulated PBMC by CT-1 at incremental concentrations 
of 10, 50, and 100 ng/ml for 15 min. Saline was used as a negative control. 
Afterwards, the phosphorylation of STAT-1, STAT-3, ERK, P38 MAPK and JNK 
in these cells was determined by Western blot analysis. After 15 min incubation 
with CT-1, a concentration dependent phosphorylation of ERK and P38 MAPK 
were found in PBMC compared with controls. However, there were no significant 
differences in phosphorylation of STAT-1, STAT-3 or JNK signaling between 
them (Fig. 9). These data showed that CT-1 activated the signaling pathway of 
ERK and P38 MAPK in PBMC, but not that of STAT-1, STAT-3 or JNK.  
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Figure 9. Significant phosphorylation of ERK and P38 MAPK but not STAT-1, 
STAT-3 or JNK in PBMC after 15 min incubation with CT-1. See next page for Legend. 
 
 
 
 
 
 42
Results 
C                                D 
                
p-JNK 
 
JNK 
p-STAT-1
STAT-1
    
  
E 
 
p-STAT-3 
 
STAT-3 
 
Figure 9. Significant phosphorylation of ERK and P38 MAPK but not STAT-1, 
STAT-3 or JNK in PBMC after 15 min incubation with CT-1. Human PBMC were 
isolated and plated on poly-l-lysine coated 6 well plate in RPMI 1640 + 10% FCS at a 
concentration of 10.000 cells/cm2. After 24 hrs, cells were incubated with CT-1 at 
incremental concentrations or saline for 15 min and total cellular lysates were prepared. 
Lysates were resolved by SDS-PAGE and transferred to membranes by Western blot. 
The blots were detected with phosphor-specific STAT-1, STAT-3, ERK, P38 MAPK or 
JNK antibodies and reprobed with STAT-1, STAT-3, ERK, P38 MAPK or JNK antibodies, 
respectively. A: STAT-1 band at 89 kDa; B: STAT-3 band at 89 kDa; C: ERK band at 
44/42 kDa; D: P38 MAPK band at 42 kDa; E: JNK band at 49 kDa. Twenty-five μg of 
total protein was loaded per lane. A significant phosphorylation of ERK and P38 MAPK 
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was observed, but no significant phosphorylation of STAT-1, STAT-3 and JNK. n=5, 
data are expressed as mean ± SEM. *P<0.05 compared with unstimulated cells. 
 
In the next sets of experiments I addressed whether CT-1 is able to induce the 
production of cytokines. For this purpose, human whole blood were incubated 
with CT-1 at a concentration of 50 ng/ml or saline as a control for 6 hrs in the 
presence of brefeldin A (10 μg/ml, an inhibitor of intracellular protein transport), 
and the intracellular accumulation of IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF-α 
after CT-1 application was determined by flow cytometry.  
After 6 hrs incubation with CT-1, a significant increased expression of TNF-α 
was observed in PBMC (6.4-fold) compared with control, but no significant 
changes were found in IL-2, IL-4, IL-5, IL-10 and IFN-γ expression (Fig. 10). 
These data indicate that under this experimental condition CT-1 induces only 
TNF-α production in PBMC.  
 
 
Figure 10. Cytokines or mediators induced by CT-1 stimulation in PBMC. Human 
blood was incubated with CT-1 at a concentration of 50 ng/ml for 6 hours in the 
presence of brefeldin A (10 μg/ml, an inhibitor of intracellular protein transport). 
Afterwards erythrocytes were lysed and cells were stained with a monoclonal antibody 
against IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF-α PE-conjugated. Results are expressed 
normalised to unstimlulated cells. A significant increased up to 6.4-fold expression of 
TNF-α was observed, but no significant changes were found in IL-2, IL-4, IL-5, IL-10, 
IFN-γ expression. n=6, data are expressed as mean ± SEM. *P<0.05 compared with 
unstimulated cells. 
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4.3  CT-1 induces the expression of TNF-α at both mRNA and 
protein levels in PBMC 
As was shown in Section 4.2, PBMC were demonstrated to be activated and 
initially observed to produce TNF-α by CT-1 sitimulation. I further validated 
whether CT-1 can promote the expression of TNF-α at both mRNA and protein 
levels in PBMC. In the first sets of experiments, cells were incubated with 
medium alone or CT-1 at a concentration of 10, 50 or 100 ng/ml for different 
periods of time various from 0.5 to 16 hrs. After the indicated time, RNA was 
isolated and TNF-α mRNA was determined by real-time-PCR. Compared with 
control, CT-1 induced a significantly upregulated expression of TNF-α mRNA in 
a concentration-dependent manner in PBMC after 1, 3 or 6 hrs incubation (all P< 
0.05). Maximal TNF-α mRNA expression was found after 1 hour incubation. 
Afterwards mRNA expression of TNF-α declined. After 16 hrs incubation with 
CT-1, there was no significant difference in mRNA expression of TNF-α 
compared with control (Fig. 11). 
Furthermore, to determine whether the CT-1 induced TNF-α expression is 
specified for CT-1 and whether this is receptor medicated, a CT-1 blocking 
antibody and an antibody blocking the gp130 (a part of the CT-1 receptor of 
gp130/LIFR-β heterodimer) were used. PBMC were stimulated with CT-1 at a 
concentration of 50 ng/ml with or without the presence of anti-CT-1 or anti-gp130 
blocking antibody for 1 hour. Afterwards TNF-α mRNA level was determined by 
real-time-PCR. Cells incubated with medium alone served as a control. Without 
the presence of CT-1 blocking antibody, CT-1 induced a significantly 
upregulated mRNA expression of TNF-α compared with control. However in the 
presence of the CT-1 or gp130 blocking antibody, there is no significant 
difference in the TNF-α mRNA level after CT-1 stimulation compared with control 
(Fig. 12). These data indicate that the increase of TNFα expression in PBMC is 
specifically caused by CT-1 and this effect is receptor mediated via gp130 
signaling. 
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Figure 11. Concentration- and time-dependent induction of TNF-α mRNA in PBMC 
after incubation with CT-1. Human PBMC were isolated and plated on poly-l-lysine 
coated 6 well plate in RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. 
After 24 hrs, cells were incubated with medium alone or CT-1 at a concentration of 10, 
50 or 100 ng/ml for different periods of time. After the indicated time, mRNA was 
isolated and TNF-α mRNA was determined by real-time-PCR. All TNF-α mRNA 
expression data were normalized to GAPDH. n=8, data are expressed as mean ± SEM. 
*P<0.05 compared with unstimulated cells. 
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Figure 12. Effect of anti-CT-1 or anti-gp130 blocking antibody on CT-1 induced 
TNF-α mRNA expression in human PBMC. PBMC were isolated and plated on 
poly-l-lysine coated 6 well plate in RPMI 1640 + 10% FCS at a concentration of 10.000 
cells/cm2. After 24 hrs, cells were incubated with or without anti-CT-1 or anti-gp130 
blocking antibody. After 30 min CT-1 (50 ng/ml) was added for additional 1 h (0 ng/ml: 
control). Afterwards mRNA was isolated and TNF-α mRNA was determined by 
real-time-PCR. All TNF-α mRNA expression data were normalized to GAPDH. n=6, 
data are expressed as mean ± SEM. *P<0.05 compared with unstimulated cells.  
 
To futher investigate the protein expression of TNF-α in PBMC after CT-1 
stimulation, cells were incubated with medium or CT-1 at a concentration of 10, 
50 or 100 ng/ml for different time periods various from 1 to 24 hrs. After the 
indicated time supernatants were tested with a commercial available ELISA for 
the presence of TNF-α protein. As shown in Figure 13, CT-1 induced TNF-α 
protein production in the supernatant of PBMC in a concentration-dependent 
manner after 3, 6 or 16 hrs of incubation (all P< 0.05). Maximal TNF-α 
concentration was found after 3 to 6 hours. Afterwards TNF-α concentration 
declined. After 24 hrs incubation with CT-1, there was no significant difference in 
TNF-α concentration compared with control (Fig. 13). These results confirmed 
the previous flow cytometry data shown in Figure 10 that TNF-α protein 
production from PBMC was up-regulated after CT-1 stimulation, and also 
indicated that CT-1 caused only a transient TNF-α release in PBMC.  
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Figure 13. Concentration- and time-dependent expression of TNF-α protein in the 
supernatant of PBMC after incubation with CT-1. Human PBMC were isolated and 
plated on poly-l-lysine coated 6 wells plate in RPMI 1640 + 10% FCS at a concentration 
of 10.000 cells/cm2. After 24 hrs, cells were incubated with medium alone or CT-1 at a 
concentration of 10, 50 or 100 ng/ml for different time periods. After the indicated 
periods supernatants were tested with a commercial available ELISA for the presence 
of TNF-α protein. n=5, data are expressed as mean ± SEM. *P<0.05 compared with 
unstimulated cells.  
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4.4  Monocytes but not lymphocytes are the PBMC subsets 
involved in the CT-1 induced TNF-α production 
PBMC consist mainly of monocytes and lymphocytes. Although TNF-α is 
produced mainly by monocytes and macrophages, it is also produced by 
lymphocytes under certain circumstance. As shown in Section 4.3, CT-1 was 
demonstrated to be able to promote the expression of TNF-α in PBMC. I further 
identified which subpopulation of PBMC was involved in the production of TNF-α 
by CT-1 stimulation.  
To overcome this issue, I incubated human blood with medium alone or CT-1 at 
a concentration of 10, 50 or 100 ng/ml for 6 hours in the presence of brefeldin A 
(10 μg/ml, an inhibitor of intracellular protein transport). Afterwards erythrocytes 
were lysed and cells were stained with a monoclonal antibody against CD3, CD4, 
CD8 or CD14 FITC-conjugated and against TNF-α PE-conjugated. Then, 
intracellular TNF-α protein in monocytes, CD4+ and CD8+ lymphocytes was 
determined by flow cytometry. Intracellular TNF-α protein determination in CD4+ 
and CD8+ lymphocytes did not show any effects of CT-1 on TNF-α expression 
(Fig. 14 A and B). In contrast, a concentration dependent significant increase of 
intracellular TNF-α after CT-1 application was found in monocytes (Fig. 14 C). 
These results showed that CT-1 induced increasing expression of TNF-α in 
PBMC was due to the activation of monocytes but not that of lymphocytes. In 
addition, these data together with that in Section 4.3 indicated that culture 
conditions did not influence CT-1 induced TNF-α production in monocytes. 
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Figure 14. Concentration-dependent induction of TNF-α intracellular protein 
expression in human peripheral blood monocytes after incubation with CT-1. See 
next page for Legend. 
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Figure 14. Concentration-dependent induction of TNF-α intracellular protein 
expression in human peripheral blood monocytes after incubation with CT-1. 
Human blood was incubated with medium alone or CT-1 at a concentration of 10, 50 or 
100 ng/ml for 6 hours in the presence of brefeldin A (10 μg/ml, an inhibitor of 
intracellular protein transport). Afterwards erythrocytes were lysed and cells were 
stained with a monoclonal antibody against CD4, CD8 or CD14 FITC-conjugated and 
against TNF-α PE-conjugated. Monocytes or lymphocytes were gated and results are 
expressed normalised to unstimlulated cells. A: CD4+ lymphocytes; B: CD8+ 
lymphocytes; C: CD14+ monocytes. n=11, data are expressed as mean ± SEM. *P<0.05 
compared with unstimulated cells. 
 
4.5  The effect of CT-1 on TNF-α expression in PBMC is 
dependent on mRNA synthesis and intracellular protein 
transport 
With the next experiments I addressed the question whether TNF-α protein 
expression is dependent on mRNA synthesis or intracellular protein transport. 
Human PBMC were isolated and plated on poly-l-lysine coated 6 well plates in 
RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. After 24 hrs, cells 
were incubated with actinomycin D (inhibitor of mRNA synthesis) or brefeldin A 
(inhibitor of intracellular protein transport). After 30 min CT-1 (50 ng/ml) or saline 
was added to the cells for additional 3 hrs. Supernatants were tested with a 
specific ELISA for the presence of TNF-α protein. As shown in Figure 15, both 
inhibition of mRNA synthesis and inhibition of intracellular protein transport were 
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able to abolish CT-1 induced TNF-α protein induction. These results showed that 
CT-1 was responsible for new protein synthesis of TNF-α protein in PBMC, and 
that TNF-α protein was secreted into the supernatant actively. 
 
Figure 15. CT-1 induced TNF-α protein expression in the supernatant of PBMC 
was abolished by actinomycin D or brefeldin A. Human PBMC were isolated and 
plated on poly-l-lysine coated 6 well plate in RPMI 1640 + 10% FCS at a concentration 
of 10.000 cells/cm2. After 24 hrs, cells were incubated with actinomycin D or brefeldin A. 
After 30 min CT-1 (50 ng/ml) was added for additional 3 hrs (0 ng/ml: control). 
Supernatants were tested with a specific ELISA for the presence of TNF-α protein. Act: 
actinomycin D (5 μg/ml), inhibits mRNA transcription, Bre: brefeldin A (10 μg/ml), 
inhibits intracellular protein transport. n=6, data are expressed as mean ± SEM. *P<0.05 
compared with unstimulated cells. 
 
4.6  CT-1 induces NFκB (nuclear factor kappa B) translocation 
into the nucleus in PBMC 
With the next experiments I addressed the underlying signaling pathway of CT-1 
induced TNF-α expression in PBMC. It has been previously shown that 
transcription factors STAT-1, STAT-3, NFκB, activator protein 1 (AP-1) and 
specificity protein 1 (SP1) were involved in the signaling pathways of various 
cytokines in PBMC (Madden, Vince et al.; Nicolet, Surfus et al. 1998; 
Sanchez-Margalet and Martin-Romero 2001; Flores, Duran et al. 2003; 
Kooijman, Coppens et al. 2006; Zimmerer, Lehman et al. 2008). However, the 
transcription factors involved in the CT-1 activated signaling pathways in PBMC 
are still unknown. To overcome this problem, human PBMC were isolated and 
plated on poly-l-lysine coated 6 well plate in RPMI 1640 + 10% FCS at a 
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concentration of 10.000 cells/cm2. After 24 hrs, cells were incubated with 
medium alone or CT-1 at a concentration of 10, 50 or 100 ng/ml for 25 min. 
Nuclear extracts were subjected to an electrophoretic mobility shift assay, then 
STAT-1/DNA, STAT-3/DNA, NFκB/DNA, AP-1/DNA and SP1/DNA complexes 
were visualized by a chemiluminescent imaging system. 
As shown in Figure 16 A, CT-1 caused a concentration-dependent NFκB 
translocation to the nucleus determined by EMSA reaching maximal 
translocation by CT-1 sitimulation at a concentration of 100 ng/ml. However, no 
significant translocation to the nucleus was found for STAT-1, STAT-3, AP-1 and 
SP1 (Fig. 16 B-E). These data suggest that PBMC exhibit a CT-1 induced 
transcription factor activation in which NFκB is involved.  
 
A                                     
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Figure 16. CT-1 induced transcription factors activity measured by EMSA. See 
next page for Legend. 
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Figure 16. CT-1 induced transcription factors activity measured by EMSA. Human 
PBMC were isolated and plated on poly-l-lysine coated 6 well plate in RPMI 1640 + 10% 
FCS at a concentration of 10.000 cells/cm2. After 24 hrs, cells were incubated with 
medium alone or CT-1 at a concentration of 10, 50 or 100 ng/ml for 25 min. Nuclear 
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extracts were subjected to an electrophoretic mobility shift assay, then STAT-1/DNA, 
STAT-3/DNA, NFκB/DNA, AP-1/DNA and SP/DNA complexes were visualized by a 
chemiluminescent imaging system. Bands corresponding to the transcription factors 
activity were quantified by densitometry and expressed in arbitrary units and normalized 
to unstimulated PBMC. A: STAT-1; B: STAT-3; C: NFκB; D: AP-1; E: SP1. n=7, data are 
expressed as mean ± SEM. *P<0.05 compared with unstimulated cells. 
 
4.7  CT-1 induced NFκB translocation into the nucleus in PBMC 
is mediated by IκB degradation 
NFκB is a rapidly acting primary transcription factor found in all cell types. It is 
involved in cellular responses to stimuli such as cytokines and stress and plays a 
key role in regulating the immune response. In unstimulated cells NFκB dimers 
are sequestered inactively in the cytoplasm by a protein complex called IκB. IκB 
inactivates NFκB by masking the nuclear localisation signals (NLS). Activation of 
NFκB occurs via degradation of IκB, a process that is initiated by its 
phosphorylation by IκB kinase (IKK). Phosphorylated IκB becomes dissociated 
from NFκB, unmasking the NLS. Phosphorylation also results in IκB 
ubiquitination and targeting to the proteasome. Then NFκB can translocate into 
the nucleus and regulate gene expression. NFκB also induces the expression of 
IκB forming a negative feedback loop. 
To test whether CT-1 induced NFκB translocation to the nucleus in PBMC is 
mediated by IκB degradation, I stimulated PBMC by CT-1 at a concentration of 
50 ng/ml or saline as a control for 5 min and then determined the concentration 
of IκB in these cells by Western blotting. After 5 min incubation with CT-1, a 
significant decrease of IκB was found in PBMC compared with sham controls 
(P< 0.05) (Fig. 17). These data showed that CT-1 induced an up to 5 min 
instantly degradation of IκB in PBMC, indicating that CT-1 caused NFκB 
activation by IκB degradation.  
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Figure 17. CT-1 induced IκB degradation measured by Western blot. Human PBMC 
were isolated and plated on poly-l-lysine coated 6 well plate in RPMI 1640 + 10% FCS 
at a concentration of 10.000 cells/cm2. After 24 hrs, cells were incubated with medium 
alone or CT-1 at a concentration of 50 ng/ml for 5 min. Afterwards PBMC were lysed. 
Lysates were resolved by SDS-PAGE and transferred to membranes by Western blot. 
The blots were detected with an anti-IκB antibody. Twenty five μg of total protein was 
loaded per lane. A significant decrease of IκB was observed after CT-1 stimulation. n=5, 
data are expressed as mean ± SEM. *P<0.05 compared with unstimulated cells. 
 
4.8  CT-1 induces TNF-α expression in PBMC via the NFκB 
pathway 
In the next sets of experiments I addressed the question whether NFκB 
translocation was responsible for CT-1 induced TNF-α expression in PBMC. 
Human PBMC were isolated and plated on poly-l-lysine coated 6 well plates in 
RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. After 24 hrs, cells 
were incubated with parthenolide (50 μM, an inhibitor of NFκB activation). After 
30 min CT-1 (50 ng/ml) was added for additional 25 min (0 ng/ml: control). 
Human umbilical vein endothelial cells (HUVEC) stimulated with TNF-α served 
as a control. Nuclear extracts were subjected to EMSA determination and 
NFκB/DNA complex was visualized by a chemiluminescent imaging system.  
As shown in Figure 18, unstimulated cells did not show significant NFκB protein 
in the nucleus, whereas CT-1 caused translocation of NFκB into the nucleus. 
Parthenolide was able to inhibit NFκB translocation into the nucleus.  
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Figure 18. Representative EMSA of CT-1 induced NFκB translocation into the 
nucleus in human PBMC was inhibited by parthenolide. Human PBMC were 
isolated and plated on poly-l-lysine coated 6 wells plate in RPMI 1640 + 10% FCS at a 
concentration of 10.000 cells/cm2. After 24 hrs, cells were incubated with parthenolide 
(50 μM, an inhibitor of NFκB activation). After 30 min CT-1 (50 ng/ml) was added for 
additional 25 min (0 ng/ml: control). Nuclear extracts were subjected to an 
electrophoretic mobility shift assay and NFκB/DNA complex was visualized by a 
chemiluminescent imaging system. Representative EMSA of CT-1 induced NFκB 
activity in PBMC was inhibited by parthenolide. HUVEC cells stimulated with TNF-α 
were used as positive control. n=6, data are expressed as mean ± SEM. *P<0.05 
compared with unstimulated cells. 
 
To further investigate the pathway responsible for NFκB translocation into the 
nucleus is essential for CT-1 induced expression of TNF-α in PBMC, I generate 
an experiment to compare the expression of TNF-α in PBMC under a condition 
with or without the presence of parthenolide (an inhibitor of NFκB activation), 
SB203580 (an inhibitor of P38 MAPK activation) and PD98059 (an inhibitor of 
ERK activation). PBMC were isolated and plated on poly-l-lysine coated 6 well 
plates in RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. After 24 
hrs, cells were incubated with parthenolide (50 μM), SB203580 (5 μM) or 
PD98059 (30 μM) respectively. After 30 min CT-1 (50 ng/ml) or saline (use as 
control) was added for additional 1 hour (for real-time-PCR determination) or 3 
hrs (for ELISA mesurement). Afterwards RNA was isolated and TNF-α mRNA 
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was determined by real-time-PCR, and the supernatants were tested with a 
specific ELISA for the presence of TNF-α protein.  
As shown in Figure 19 and 20, CT-1 caused a significant elevated expression of 
TNF-α at both mRNA and protein level in PBMC compared with control. In the 
presence of parthenolide the CT-1-induced expression of TNF-α decreased 
significantly to a level that was not significantly different from the control. In 
contrast, neither SB203580 nor PD98059 had an effect on the CT-1-induced 
expression of TNF-α. In the presence of SB203580 or PD98059 there is still a 
significant difference in the expression of TNF-α between CT-1 stimulation and 
the control. These data showed that CT-1 induced TNF-α expression in PBMC 
was able to completely inhibited by parthenolide at both protein and mRNA level, 
but not by SB203580 or PD98059, suggesting that CT-1 induced TNF-α 
expression is due to NFκB activation but not depended on P38 MAPK or ERK 
activation. 
 
 
Figure 19. Effect of signal inhibitors on CT-1 induced TNF-α mRNA expression in 
human PBMC. PBMC were isolated and plated on poly-l-lysine coated 6 wells plate in 
RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. After 24 hrs, cells were 
incubated with parthenolide (50 μM, an inhibitor of NFκB activation), SB203580 (5 μM, 
an inhibitor of P38 MAPK activation) or PD98059 (30 μM, an inhibitor of ERK activation). 
After 30 min CT-1 (50 ng/ml) was added for additional 1 h (0 ng/ml: control). Afterwards 
RNA was isolated and TNF-α mRNA was determined by real-time-PCR. All TNF-α 
mRNA expression data were normalized to GAPDH. n=6, data are expressed as mean 
± SEM. *P<0.05 compared with unstimulated cells.  
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Figure 20. Effect of signal inhibitors on CT-1 induced TNF-α protein expression in 
human PBMC. PBMC were isolated and plated on poly-l-lysine coated 6 well plates in 
RPMI 1640 + 10% FCS at a concentration of 10.000 cells/cm2. After 24 hrs, cells were 
incubated with parthenolide (50 μM, an inhibitor of NFκB activation), SB203580 (5 μM, 
an inhibitor of P38 MAPK activation) or PD98059 (30 μM, an inhibitor of ERK activation). 
After 30 min CT-1 (50 ng/ml) was added for additional 3 h (0 ng/ml: control). Afterwards 
supernatants were tested with a specific ELISA for the presence of TNF-α protein. n=5, 
data are expressed as mean ± SEM and normalized to unstimulated cells. *P<0.05 
compared with unstimulated cells.  
 
To further examine the effect of parthenolide on CT-1 induced TNF-α protein 
intracellular expression in human peripheral blood monocytes, human blood was 
incubated with brefeldin A (10 μg/ml, an inhibitor of intracellular protein transport) 
and parthenolide (50 μM, an inhibitor of NFκB activation). After 30 min CT-1 (50 
ng/ml) was added for additional 6 hrs (0 ng/ml: control). Afterwards erythrocytes 
were lysed and cells were stained with a monoclonal antibody against CD14 
FITC-conjugated and against TNF-α PE-conjugated. Using flow cytometry 
monocytes showed an increase of intracellular TNF-α after CT-1 application 
which could be completely inhibited by parthenolide (Fig. 21). Parthenolide alone 
did not show a significant effect on TNF-α expression in unstimulated cells. 
These results show that CT-1 induced TNF-α in PBCM independent of culture 
conditions and independent of determination methodes and NFκB seems to be 
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essential for the effect of CT-1 on TNF-α induction in PBMC. 
 
 
Figure 21. Effect of parthenolide on CT-1 induced TNF-α protein intracellular 
expression in human peripheral blood monocytes. Human blood was incubated with 
brefeldin A (10 μg/ml, an inhibitor of intracellular protein transport) and parthenolide (50 
μM, an inhibitor of NFκB activation). After 30 min CT-1 (50 ng/ml) was added for 
additional 6 h (0 ng/ml: control). Afterwards erythrocytes were lysed and cells were 
stained with a monoclonal antibody against CD14 FITC-conjugated and against TNFα 
PE-conjugated. Monocytes were gated and results are expressed normalised to 
unstimlulated monocytes. n=6, data are expressed as mean±SEM. *P<0.05 compared 
with unstimulated cells, **P<0.05 compared with cells stimulated with 50 ng/ml CT-1. 
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5 Discussion 
In CHF, activation of the immune system occurs, which results in the production 
and release of proinflammatory cytokines, activation of the complement system, 
and production of autoantibodies. All of these pathophysiological processes can 
cause a progression of CHF. Recent experimental evidence suggests a pathway 
of cytokine release by cardiac cells, both myocytes and nonmyocytes, in 
response to hemodynamic stress. Following hemodynamic load mice developed 
cardiac dysfunction in association with a wide array of activation of 
proinflammatory cytokines and a decrease in anti-inflammatory cytokines in 
cardiac cells with little or no inflammatory infiltrates, indicating that the 
hemodynamic load alone is capable of producing cardiac inflammation (Celis, 
Torre-Martinez et al. 2008). Although in that study the actions of cytokines 
released by cardiac cells are locally limited in the heart, from these findings I was 
enlightened to form an idea that substances released by cardiac cells might also 
be released into the circulation and exert endocrine or exocrine effects to initiate 
or participate in the inflammatory response in heart failure.  
To verify this idea, I looked for a potential substance which was exclusively 
produced by the failing cardiac cells and capable of inducing an inflammatory 
response. The observations that CT-1, produced predominantly by heart, is 
increasingly expressed and secreted via the coronary sinus into the peripheral 
circulation in CHF, and that CT-1 is a strong acute-phase mediator to induce a 
dose-dependent production of several acute phase proteins (Robledo, Guillet et 
al. 1997), suggest that CT-1 could play an important role in the regulation of the 
inflammatory response seen in CHF, I therefore focus my interest of concern on 
CT-1 as a candidate of potential substance for study.  
Because in CHF many proinflammatory cytokines are elevated and PBMC are 
activated, it is not easy to study the effect of a single cytokine in PBMC from 
patients with CHF. To elucidate a potential effect of CT-1 in CHF on PBMC, I 
used an in vitro cell culture model of PBMC from healthy volunteers and 
stimulated them with CT-1 in various concentrations and various experimental 
condistions.  
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This study is the first to demonstrate that CT-1 activates PBMC via gp130/ 
LIFR-β receptor and induces TNF-α production via NFκB signaling pathway in 
monocytes but not in lymphocytes. The results of this work reveal a new 
mechanism of immune activation in heart failure and elucidate a potential role of 
CT-1 in the pathophysiology of CHF. In addition, the data illustrate that heart is 
not only just a target of inflammation in CHF, but also seems to play a role in the 
activation of the proinflammatory state by secreting CT-1 into the circulation. 
 
5.1  gp130 and LIFR-β are co-expressed in PBMC 
Studies on the activities of CT-1 and its receptor have shown that, in several in 
vitro assays, CT-1 acts similarly to cytokines of the IL-6 family, and that CT-1 
could bind to and induce biological responses via LIFR complex (gp130/LIFR-β 
heterodimer) (Pennica, Shaw et al. 1995). 
Although gp130 is ubiquitously expressed, the number of cells that respond to a 
certain IL-6-type cytokine is limited, since the expression of the other receptor 
subunits is more restricted and tightly regulated. To the best of my knowledge, in 
the present study, I found for the first time that CT-1 receptor subunits gp130 and 
LIFR which were requested to build a heterodimer for CT-1 action were both 
expressed on PBMC, suggesting that CT-1 might have an effect on these cells. I 
therefore considered the PBMC a suitable experimental model to further study 
CT-1 action. 
In addition, I also observed that the application of CT-1 to PBMC did not alter the 
expression of gp130 and LIFR-β, which would ensure a high affinity and efficacy 
to create ligand-receptor complex and further initiate a response.  
 
5.2  CT-1 activates PBMC 
Activated PBMC are characterized by activated signaling pathway and 
increased expression of several cytokines or mediators of inflammation. The 
present study showed an activation of signaling pathways and production of 
cytokine of TNF-α induced by CT-1 in PBMC. These data confirmed that CT-1 is 
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able to directly activate PBMC in the absence of any additional stimuli. This 
activation exhibits a distinct profile of signaling pathways activity and cytokines 
expression.  
 
5.2.1 CT-1 activates signaling pathways in PBMC 
In the present study, I determined the CT-1 induced signaling pathways in 
PBMC. I found significant phosphorylation of ERK and P38 MAPK in PBMC 
compared with controls after incubation with CT-1. These results demonstrate 
that CT-1 can activate the ERK and P38 MAPK signaling pathways in PBMC, 
which is in good aggreement with previous studies in PBMC that show active 
pathways of ERK and P38 MAPK after stimulation of various stimuli, e.g. 
lipopolysaccharide (LPS), insulin-like growth factor-1, rhizoctonia bataticola 
lectin, prolactin, vibrio vulnificus or 5-hydroxytryptamine (Vanlandschoot, 
Roobrouck et al. 2002; Cloëz-Tayarani, Kayyali et al. 2004; Kooijman, Coppens 
et al. 2006; Kim, Goo et al. 2009; Pujari, Nagre et al. 2010). In contrast to 
previous studies that showed an active STAT-1, STAT-3 or JNK signaling in 
PBMC (Dogusan, Hooghe et al. 2001; Sanchez-Margalet and Martin-Romero 
2001; Kooijman, Coppens et al. 2006; Zimmerer, Lehman et al. 2008), the 
results presented here demonstrate no activation of STAT-1, STAT-3 or JNK 
pathway in PBMC after CT-1 stimulation. Therefore, these data showed that the 
signaling induced by CT-1 exhibits a distinct pattern of activation in ERK and 
P38 MAPK signaling but not in STAT-1, STAT-3 or JNK, which will provide a 
basis for future studies on the specific effects via these distinct signaling 
pathways in PBMC.  
As described in the Introduction section, the signaling pathway downstream 
from gp130 consists of three distinct pathways. It is likely that CT-1 achieves its 
effects by certain pathway(s) depending on the particular effect examined or the 
cell type studied. While several studies agree on the effects mediated by the 
MAPK pathway, our knowledge about the actions mediated by the JAK/STAT 
pathway are contrasting. MAPK pathways might be involved in CT-1's capacity 
to promote the survival of terminally differentiated cell types. These effects were 
significantly blocked after treatment with PD98059, a MAPK kinase (MEK) 1 
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inhibitor, that, in contrast, did not block the activation of STAT3 or the 
hypertrophic response of cardiomyocytes following stimulation of CT-1 (Sheng, 
Knowlton et al. 1997). Recent studies have confirmed the involvement of the 
p42/44 MAPK pathway in protective effects of CT-1 (Brar, Stephanou et al. 2001; 
Liao, Brar et al. 2002; Railson, Liao et al. 2002). On the other hand, the role of 
the JAK/STAT pathway is controversial. The majority of studies suppose that the 
activation of STAT3 promotes myocardial hypertrophy (Sheng, Knowlton et al. 
1997; Kunisada, Tone et al. 1998; Kunisada, Negoro et al. 2000; Railson, Liao et 
al. 2002); however, according to a recent study, the major pathway responsible 
for the hypertrophic response to CT-1 is not the JAK/STAT3 pathway nor the 
MEK/ERK1/2 pathway, but the pathway, MEK5/ERK5 (Takahashi, Saito et al. 
2005). Moreover, the JAK/STAT pathway is implicated in beneficial mechanism, 
such as, transducing protective signals against doxorubicin-induced (Kunisada, 
Negoro et al. 2000) and postpartum cardiomyopathy (Hilfiker-Kleiner, Kaminski 
et al. 2007), protecting cardiomyocytes from ischemic (Negoro, Kunisada et al. 
2000) and oxidative stress (Negoro, Kunisada et al. 2001), promoting myocardial 
angiogenesis and, consequently, tissue oxygenation during reperfusion, and 
controlling interstitial collagen metabolism with a reduction in cardiac fibrosis 
(Hilfiker-Kleiner, Hilfiker et al. 2004). Concerning the PI3K/Akt pathway, it 
promotes, as does the p42/44 MAPK pathway, cardiac myocyte survival against 
doxorubicininduced apoptosis (Negoro, Oh et al. 2001). It is interesting to note 
that, regarding cardioprotection against non-ischemic stimuli (Lopez, Diez et al. 
2005) and re-oxygenation (Brar, Stephanou et al. 2001) CT-1 mediated, neither 
activation of the MEK1, p42/44 pathway nor PI3K/Akt alone is sufficient. 
Therefore MAPK and PI3K/Akt could cooperate in CT-1 mediated pro-survival 
effects (Kuwahara, Saito et al. 2000; Brar, Stephanou et al. 2001; Lopez, Diez et 
al. 2005). 
 
5.2.2 CT-1 promotes cytokines production from PBMC 
PBMC are a very important part of our immune system. PBMC consist mainly of 
monocytes and lymphocytes. Several important cytokines that act as mediators 
and regulators of immune processes are well known to be produced by these 
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cells. In response to pathogens and stimulation of specific cell-surface receptors, 
PBMC with heterogeneous multifunctional cellular population are activated and 
produce cytokines, e.g. TNF-α, IL-2, IL-4, IL-5, IL-10 and IFN-γ. 
Our result showed that CT-1 activated PBMC to induce TNF-α production in 
these cells. After 6 hrs incubation with CT-1, a significantly increased up to 
6.4-fold expression of TNF-α protein was observed in PBMC, but no significant 
changes were found in IL-2, IL-4, IL-5, IL-10 and IFN-γ expression. These data 
confirm that CT-1 can activate PBMC to produce cytokine, in which TNF-α is 
involved but not the cytokines of IL-2, IL-4, IL-5, IL-10 and IFN-γ. 
In addition, given that TNF-α is primarily screted from monocytes and 
macrophages but not from lymphocytes, while IL-2, IL-4, IL-5, IL-10 and IFN-γ 
are produced primarily by lymphocytes (IL-2 is produced by helper T 
lymphocytes (Th cells), IL-4 by macrophages and Th2 cells, IL-5 by Th2 cells, 
IL-10 by monocytes, macrophages and Th2 cells, INF-γ by Th1 cells, Tc and 
natural killer cells), my results also indicate that this distinct cytokine production 
profile evoked by CT-1, which exhibits a unique up-regulated expression of 
TNF-α without IL-2, IL-4, IL-5, IL-10 and IFN-γ expression, suggests that the 
activation of PBMC might exclusively proceed in monocytes subset. This 
concern has been discussed later in this dissertation.  
 
5.3  CT-1 induces the expression of TNF-α at both mRNA and 
protein levels in PBMC 
The present study demonstrates that CT-1 alone is able to induce the expression 
of TNFα at both mRNA and protein level in a concentration- and time-dependent 
manner in PBMC from healthy volunteers. This effect is exclusively mediated via 
CT-1 receptor - gp130/LIFR-β heterodimer. My data indicate that CT-1, secreted 
from cardiac cells into the peripheral circulation in CHF, might activate PBMC to 
produce TNF-α and therefore CT-1 may be at least in part responsible for the 
elevated circulating levels of TNF-α in these patients.  
Previous studies have shown that TNF-α was increased in serum of patients with 
CHF and correlated with the severity of heart failure, cachexia (Anker, Chua et al. 
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1997) and clinical outcome (Anker, Ponikowski et al. 1997). TNF-α may be 
involved in the progression of CHF because high levels of TNF-α can induce left 
ventricular dysfunction, ventricular remodelling, cardiomyopathy and pulmonary 
edema (Mann and Young 1994; Kelly and Smith 1997). Cultured human PBMC 
can synthesize and secrete TNF-α. In heart failure, both the heart itself as well 
as activated monocytes are able to secrete TNF-α (Torre-Amione, Kapadia et al. 
1996; Vonhof, Brost et al. 1998). Furthermore, the capacity of PBMC of CHF 
patients to secrete TNF-α is increased compared with healthy control. My data 
are in good agreement with these former studies. 
In my experiments both TNF-α mRNA expression and TNF-α protein production 
of PBMC showed a large standard variation. First one explanation for the large 
standard deviation may be a different genetic susceptibility of PBMC from 
different persons to stimuli (Hu, Luo et al. 2006). Second, I used the low basal 
mRNA or protein levels as basis of normalization explaining the large standard 
variation.  
The fact that the increase of TNF-α mRNA expression after CT-1 application is 
much higher compared to the increase of protein in the supernatant may be 
explained methodically.  
In addition, in my experiments I performed two methods (ELISA and flow 
cytometry) to determine the TNF-α protein production of PBMC in two different 
culture conditions of isolated purified PBMC cultures and human whole blood 
cultures respectively. In both of these two culture conditions an increasing 
expression of TNF-α protein induced by CT-1 was observed in PBMC, indicating 
that CT-1 induced TNF-α production from PBMC was independent of culture 
conditions and independent of protein determination methods. 
As we can seen above, CT-1 can promote TNF-α mRNA expression and protein 
secretion from PBMC. It raised my another interest: What is TNF-α protein 
secretion dependent on? Is it dependent on mRNA synthesis or intracellular 
protein transport? To overcome these problems, I used actinomycin D to inhibite 
mRNA synthesis and brefeldin A to inhibite intracellular protein transport in 
PBMC 30 min before CT-1 incubation. I found that both inhibition of mRNA 
synthesis by actinomycin D and inhibition of intracellular protein transport by 
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brefeldin A were able to abolish CT-1 induced TNF-α protein production in the 
supernatant. These results demonstrated that CT-1 was responsible for new 
protein synthesis of TNF-α protein in PBMC, and that TNF-α protein was 
secreted into supernatant actively. 
 
5.4  CT-1 activates PBMC to produce TNF-α: a new mechanism 
of upregulated synthesis of TNF-α in heart failure 
It has been shown that activated monocytes are responsible for increased 
TNF-α serum concentrations in CHF. Monocytes may be activated by LPS or 
other ETX from the gut because the barrier function of the gut by cardial edema 
is disturbed and bacteria can easily translocate from the gut lumen into the blood 
(Anker, Egerer et al. 1997; Brunkhorst, Clark et al. 1999; Niebauer, Volk et al. 
1999; Conraads, Jorens et al. 2004; Krack, Sharma et al. 2005; Torre-Amione 
2005). Siminarly, I found an activation of PBMC and a significantly expression of 
TNF-α in these cells in the present study. However, unlike the previous studies, I 
found that PBMC were actived by CT-1 but not by LPS or other ETX, suggesting 
that CT-1 alone is sufficient to activate PBMC to produce TNF-α in these 
experimental conditions.  
My data suggest at least in theory a new mechanism for TNF-α production of 
PBMC in heart failure. In response to ventricular stretch due to hemodynamic 
stress, cardiac cells significantly upregulate CT-1 secretion into the peripheral 
circulation (Jougasaki, Leskinen et al. 2003). Once CT-1 is released into 
peripheral circulation, it activates PBMC and is able to induce TNF-α production 
from these cells in the absence of other stimuli, cytokines or pathogens, e.g. 
LPS.  
The mechanism presented herein might also explain why TNF-α may be still 
elevated in CHF even after edema were treated successfully with diuretics and 
the integrity of gut mucosa was restored. Furthermore, my data support a study 
from Petretta et al. that TNF-α is not produced by the failing heart or the gut in 
patients with mild to severe heart failure (Petretta, Condorelli et al. 2000).  
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5.5  Monocytes but not lymphocytes are the PBMC subsets 
involved in the CT-1 induced TNF-α production 
Although TNF-α is thought to be produced primarily by monocytes and 
macrophages, there are several reports that demonstrate the ability of T 
lymphocytes to produce and release TNF-α (Fischer, Dohlsten et al. 1990; 
Akatsuka, Imanishi et al. 1994; Weill, Gay et al. 1996; Higuchi, Nagasawa et al. 
1997; Yan, Yang et al. 1999). In the present study, intracellular TNF-α protein 
determination in CD4+ and CD8+ lymphocytes did not show any effects of CT-1 
on TNF-α expression. In contrast, a concentration dependent significant 
increase of intracellular TNF-α after CT-1 application was found in monocytes. 
The present data show that CT-1 induced increasing expression of TNF-α in 
PBMC is not from the subpopulation of lymphocytes but from monocytes under 
these in vitro conditions.  
Production of TNF-α after CT-1 stimulation in the subset of monocytes may 
reflect monocytes differentiation, because TNF-α has been described as an 
autocrine regulator of monocyte/macrophage differentiation (Witsell and Schook 
1992). Monocytes activation and differentiation into macrophages will further 
exert their effects on inflammatory reaction and immunoregulation with 
lymphocytes.  
Moreover, their role in heart failure is not restricted to inflammatory reaction. 
There is good evidence of the important roles of monocytes/macrophages in 
various cardiovascular disorders associated with heart failure. Monocytes have 
been involved in atherosclerosis, the pathophysiological process underlying 
coronary artery disease and subsequently of ischaemic cardiomyopathy (Ross 
1999). Ischaemia-induced myocardial damage and subsequently myocardial 
remodelling and heart failure have also been associated with monocyte 
infiltration into the damaged myocardium (Roberts, Maclean et al. 1985; Swirski, 
Weissleder et al. 2009).  
Therefore, as shown in my data the activation in monocytes induced by CT-1 
means much more than a cytokine production, but suggests extensive effects of 
it on the pathophysiological process leading to heart failure.  
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5.6  CT-1 induces NFκB translocation into the nucleus in PBMC 
5.6.1  NFκB  
NFκB is a protein complex that controls the transcription of several genes. NFκB 
is found in almost all animal cell types and is involved in cellular responses to 
stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized 
low-density lipoprotein, and bacterial or viral antigens. NFκB plays a key role in 
regulating the immune response to infection. Incorrect regulation of NFκB has 
been linked to cancer, inflammatory and autoimmune diseases, septic shock, 
viral infection, and improper immune development.  
There are five proteins in the mammalian NFκB family, as is shown in Table 2 
(Nabel and Verma 1993).  
 
Table 2  mammalian NFκB family members 
Class Protein Aliases Gene 
NFκB1 p105 → p50 NFKB1 I 
NFκB2 p100 → p52 NFKB2 
RelA p65 RELA 
RelB  RELB II 
c-Rel  REL 
(Nabel and Verma 1993) 
 
All proteins of the NFκB family share a Rel homology domain in their N-terminus. 
A subfamily of NFκB proteins, including RelA, RelB, and c-Rel, have a trans- 
activation domain in their C-termini. In contrast, the NFκB1 and NFκB2 proteins 
are synthesized as large precursors, p105, and p100, which undergo processing 
to generate the mature NFκB subunits, p50 and p52, respectively. The 
processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway 
and involves selective degradation of their C-terminal region containing ankyrin 
repeats. Whereas the generation of p52 from p100 is a tightly-regulated process, 
p50 is produced from constitutive processing of p105 (Karin and Ben-Neriah 
2000; Senftleben, Cao et al. 2001) NFκB family members share structural 
homology with the retroviral oncoprotein v-Rel, resulting in their classification as 
NFκB/Rel proteins (Gilmore 2006) (Fig. 22). 
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Figure 22. Schematic diagram of NFκB protein structure. There are two structural 
classes of NFκB proteins: class I (top) and class II (bottom). Both classes of proteins 
contain a N-terminal DNA-binding domain (DBD), which also serves as a dimerization 
interface to other NFκB transcription factors and, in addition, binds to the inhibitory IκBα 
protein. The C-terminus of class I proteins contains a number of ankyrin repeats and 
has transrepression activity. In contrast, the C-terminus of class II proteins has a 
transactivation function (Brasier 2006; Gilmore 2006; Perkins 2007). 
 
5.6.2  Activation of NFκB 
NFκB is important in regulating fast cellular responses because it belongs to the 
category of "rapid-acting" primary transcription factors, i.e., transcription factors 
that are present in cells in an inactive state and do not require new protein 
synthesis to be activated. This allows NFκB to be a first responder to harmful 
cellular stimuli. Known inducers of NFκB activity are highly variable and include 
reactive oxygen species, TNF-α, IL-1β, LPS, isoproterenol, cocaine, and ionizing 
radiation (Renard, Zachary et al. 1997; Basu, Rosenzweig et al. 1998; Takemoto, 
Yoshiyama et al. 1999; Chandel, Trzyna et al. 2000; Hargrave, Tiangco et al. 
2003; Qin, Wilson et al. 2005; Fitzgerald, Meade et al. 2007). 
Furthermore, many bacterial products and stimulation of a wide variety of 
cell-surface receptors lead to NFκB activation and rapid changes in gene 
expression (Gilmore 2006). The identification of Toll-like receptors (TLRs) as 
specific pattern recognition molecules and the finding that stimulation of TLRs 
leads to activation of NFκB improved our understanding of how different 
pathogens activate NFκB. For example, studies have identified TLR4 as the 
receptor for the LPS component of GNB (Doyle and O'Neill 2006). TLRs are key 
regulators of both innate and adaptive immune responses (Hayden, West et al. 
2006). 
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Unlike RelA, RelB, and c-Rel, the p50 and p52 NFκB subunits do not contain 
transactivation domains in their C terminal halves. Nevertheless, the p50 and 
p52 NFκB members play critical roles in modulating the specificity of NFκB 
function. Although homodimers of p50 and p52 are, in general, repressors of κB 
site transcription, both p50 and p52 participate in target gene transactivation by 
forming heterodimers with RelA, RelB, or c-Rel (Li and Verma 2002). In addition, 
p50 and p52 homodimers also bind to the nuclear protein Bcl-3, and such 
complexes can function as transcriptional activators (Franzoso, Bours et al. 
1992; Bours, Franzoso et al. 1993; Fujita, Nolan et al. 1993) (Fig. 23). 
 
Figure 23. Mechanism of NFκB action. The NFκB heterodimer between Rel and p50 
proteins is used as an example. While in an inactivated state, NFκB is located in the 
cytosol complexed with the inhibitory protein IκBα. Through the intermediacy of integral 
membrane receptors, a variety of extracellular signals can activate the enzyme IKK. IKK, 
in turn, phosphorylates the IκBα protein, which results in ubiquitination, dissociation of 
IκBα from NFκB, and eventual degradation of IκBα by the proteosome. The activated 
NFκB is then translocated into the nucleus where it binds to specific sequences of DNA 
called response elements. The DNA/NFκB complex then recruits other proteins such as 
coactivators and RNA polymerase, which transcribe downstream DNA into mRNA, 
which, in turn, is translated into protein, which results in a change of cell function 
(Brasier 2006; Gilmore 2006; Perkins 2007). 
 
 
 71
Discussion 
5.6.3  Activation of NFκB in PBMC by CT-1  
Previous studies have found an activation of the NFκB system in patients with 
heart failure. The myocardial tissue of patients with CHF of different etiologies 
exhibits overexpression of NFκB and of the genes that it regulates, such as 
TNF-α, NO, leukocyteadhesion molecules, and metalloproteinases (Valen, Yan 
et al. 2001). Peripheral blood cells were found an activation of the NFκB system 
in patients with CHF. Jankowska et al. reported an activation of the NFκB system 
in peripheral blood leukocytes in CHF patients measured by 
immuncytochemistry (Jankowska, von Haehling et al. 2005). Siednienko et al. 
found an augmented activation of NFκB activation in blood mononuclear cells 
using EMSA in patients with CHF compared with healthy controls (Siednienko, 
Jankowska et al. 2007). However, the exact pathway responsible for NFκB 
activation in CHF is still unknown and remains to be elucidated. 
In the present study, CT-1 caused a concentration-dependent NFκB 
translocation into the nucleus in PBMC, indicating a CT-1 induced transcription 
factor activation. These data therefore suggest at least in theory a mechanism 
responsible for NFκB activation in CHF: In response to ventricular stretch due to 
hemodynamic stress, cardiac cells significantly upregulate CT-1 secretion into 
the peripheral circulation, which causes subsequent NFκB activation in PBMC 
from patients with CHF.  
In addition, besides the known inducers of NFκB activity and its generally 
accepted receptors, I found that activation of NFκB can also be evoked by CT-1 
stimulation via its gp130/LIFR-β receptor. These results indicate a new inducer 
of NFκB activity in PBMC and a new receptor for the NFκB signaling pathway.  
 
5.7  CT-1 induced NFκB translocation into the nucleus in PBMC 
is mediated by IκB degradation 
As shown in Figure 23, in unstimulated cells, the NFκB dimers are sequestered 
in the cytoplasm by a family of inhibitors, called IκBs, which are proteins that 
contain multiple copies of a sequence called ankyrin repeats. By virtue of their 
ankyrin repeat domains, the IκB proteins mask the NLS of NFκB proteins and 
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keep them sequestered in an inactive state in the cytoplasm (Jacobs and 
Harrison 1998). 
Activation of NFκB is initiated by the signal-induced degradation of IκB proteins. 
This occurs primarily via activation of a kinase called IKK. IKK is composed of a 
heterodimer of the catalytic IKK alpha and IKK beta subunits and a "master" 
regulatory protein termed NFκB essential modulator or IKK gamma. When 
activated by signals, usually coming from the outside of the cell, the IκB kinase 
phosphorylates two serine residues located in an IκB regulatory domain. When 
phosphorylated on these serines (e.g., serines 32 and 36 in human IκBα), the 
IκB inhibitor molecules are modified by a process called ubiquitination, which 
then leads them to be degraded by a cell structure called the proteasome (Lo, 
Basak et al. 2006; Basak, Kim et al. 2007) (Fig. 23). 
With the degradation of IκB, the NFκB complex is then freed to enter the nucleus 
where it can 'turn on' the expression of specific genes. The activation of these 
genes by NFκB then leads to the given physiological response, for example, an 
inflammatory or immune response, a cell survival response, or cellular 
proliferation. NFκB turns on expression of its own repressor, IκBα. The newly 
synthesized IκBα then re-inhibits NFκB and, thus, forms an auto feedback loop, 
which results in oscillating levels of NFκB activity (Nelson, Ihekwaba et al. 2004) 
(Fig. 23). 
In the present study, I found that CT-1 caused a decrease of IκB after 5 minutes 
of incubation, suggesting that CT-1 caused NFκB activation is medicated by IκB 
degradation. These data indicate that CT-1 induced NFκB activation is 
consistent with the other inducers via IκB degradation, which also supports 
previous finding in the mechanism of NFκB activation.  
 
5.8  CT-1 induces TNF-α expression via NFκB pathway 
5.8.1  Intracellular mechanisms leading to TNF-α production 
In most cell types, the TNF-α gene is silenced (Beutler and Kruys 1995) but can 
be accessed in cell types that express the signaling mechanisms and 
transcriptional apparatus required for TNF-α production. Because monocytes 
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and macrophages are the main TNF-α source, mechanisms of TNF-α production 
have been studied almost exclusively in these cells. Although there are 
undoubtedly different cell types and different stimuli, the following signaling 
mechanisms describe what is presently known concerning LPS-stimulated 
macrophage TNF-α production (Sweet and Hume 1996).  
 
 
Figure 24. Intracellular mechanisms that lead to TNF-α production. LPS interaction 
with CD14 leads to rapid intracellular tyrosine phosphorylation of Ras [by 
phosphotyrosine kinase (PTK)], a process that initiates the protein kinase cascade, 
leading to TNF-α production. Ras activates Raf-1/ mitogenactivated protein kinase 
kinase, which activate members of the MAPK family of protein kinases, extracellular 
signal-related kinase, stress-activated protein kinase, and Jun nuclear kinase. The P38 
MAPK appears to be an important MAPK in the cascade leading to TNF-α gene 
induction. NFkB is activated by IkB phosphorylation (which disengages its inhibitory 
subunit, IkB) and translocates to the nucleus to activate TNF-α promoters. Once 
translated to pro-TNF-α in the cytosol, myristoylation permits membrane insertion, 
where pro-TNF-α remains until it is cleaved to its mature form by tumor necrosis 
factor-alpha converting enzyme (TACE) (Meldrum 1998.).  
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LPS binds a variety of serum proteins that either positively or negatively 
influence the macrophage-mediated proinflammatory response (Ulevitch and 
Tobias 1995). Of these, LPS-binding protein (LBP) is the best characterized. 
LBP facilitates LPS binding to CD14 (Figs. 24). CD14 is the macrophage-specific 
surface receptor for LPS. Although not absolutely required for LPS-induced 
macrophage activation (at high doses LPS can bypass CD14 by triggering the 
p80 LPS receptor directly), LBP is required for LPS-CD14 interaction. Under 
normal circumstances, LPS-LBP interaction with CD14 is obligate for the 
intracellular signals that triggers LPS-induced TNF-α production.  
As shown in Figure 24, LPS-LBP-CD14 interaction provokes rapid activation of 
protein tyrosine kinase (PTK) causing tyrosine phosphorylation of several 
intracellular protein kinases (Weinstein, Gold et al. 1991; Weinstein, Sanghera et 
al. 1992; Han, Lee et al. 1993; Weinstein, June et al. 1993; Shapira, Takashiba 
et al. 1994; Sanghera, Weinstein et al. 1996). PTK activates a pathway involving 
Ras/Raf-1/MEK/MAPKs/NFkB (Buscher, Hipskind et al. 1995; Derijard, 
Raingeaud et al. 1995; Levitzki 1995; Levitzki and Gazit 1995). Ras is an early 
target of activated PTK and is able to interact directly with Raf-1 (Howe, Leevers 
et al. 1992; Moodie, Willumsen et al. 1993; Van Aelst, Barr et al. 1993). Raf-1 is 
an important intermediate to MAPK activation (Howe, Leevers et al. 1992; 
Moodie, Willumsen et al. 1993; Van Aelst, Barr et al. 1993; Buscher, Hipskind et 
al. 1995). LPS resulted in PTK-dependent rapid phosphorylation and activation 
of Raf-1(Reimann, Buscher et al. 1994). Raf-1/MEK appears to activate 
members of the MAPK family of protein kinases; of these the P38 MAPK 
appears to be a pivotal MAPK in the cascade leading to TNF-α gene induction 
(Han, Lee et al. 1994; Lee, Laydon et al. 1994; Han, Richter et al. 1995; Shapiro 
and Dinarello 1995; Lee and Young 1996). In most cells, NFkB exists in a latent 
state, unable to induce gene transcription (Malinin, Boldin et al. 1997). In this 
state, NFkB is bound to its inhibitory proteins, IkB, which mask its nuclear 
localization site; however, after phosphorylation of IkB, the NFkB-IkB complex is 
disrupted and IkB is degraded (Li and Sedivy 1993; Trede, Tsytsykova et al. 
1995; Sweet and Hume 1996). Once liberated from IkB, NFkB translocates from 
the cytoplasm to the nucleus, where it docks to DNA at one of four NFkB binding 
(TNF-α promoter) sites (Shakhov, Collart et al. 1990) and initiates the 
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transcription of TNF-α gene. IkB may be phosphorylated by MAPKs (Malinin, 
Boldin et al. 1997); however, it is noteworthy that Raf-1, a relatively upstream 
component of this pathway, is also capable of activating NFkB (Howe, Leevers 
et al. 1992; Li and Sedivy 1993). Redundant or ‘‘skip’’ activation sequences may 
be designed to ensure NFkB activation following LPS challenge. Once TNF-α 
gene transcription occurs, TNF-α mRNA is translated into the 26-kDa TNF-α 
precursor (pro-TNF-α) in the cytoplasm (McGeehan, Becherer et al. 1994; 
Mohler, Sleath et al. 1994; Dinarello and Margolis 1995). Myristoylation in the 
cytoplasm facilitates membrane insertion/association, where it is cleaved by 
TACE. The mature 17-kDa TNF-α is then released into the extracellular space. 
Thus LPS interaction with CD14 leads to rapid intracellular tyrosine 
phosphorylation of Ras, a process that initiates the protein kinase cascade 
leading to NFkB activation and TNF-α production. 
 
5.8.2  CT-1 induces TNF-α expression via NFκB pathway 
In the present study, CT-1 caused translocation of NFκB into the nucleus of 
PBMC, which was completely inhibited by parthenolide, an inhibitor of NFκB 
activation. The fact that parthenolide is able to inhibit CT-1 induced TNF-α 
expression in PBMC at both protein and mRNA level, suggesting that NFκB 
translocation is essential for CT-1 induced TNF-α expression. In addition, these 
data also confirm that CT-1 promoting TNF-α production is in good agreement 
with the above-mentioned signaling pathway of NFκB.  
As described in Section 5.8.1, there are two pathways in the NFkB activation for 
TNF-α expression: Raf-1/MEK activates members of the MAPK family of protein 
kinases (i.e. P38 MAPK and ERKs) leading to IkB phosphorylation and 
subsequent activation of NFkB (Han, Lee et al. 1994; Lee, Laydon et al. 1994; 
Han, Richter et al. 1995; Shapiro and Dinarello 1995; Lee and Young 1996), or 
Raf-1 directly activates NFkB as ‘‘skip’’ activation sequences (Howe, Leevers et 
al. 1992; Li and Sedivy 1993). In the present study, neither SB203580 (inhibitor 
of P38 MAPK) nor PD98059 (inhibitor of ERK) are capable of interruption of 
CT-1-induced TNF-α expression in PBMC, suggesting that CT-1 might activate 
NFkB via Raf-1 directly as ‘‘skip’’ activation sequences but not via 
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Raf-1/MEK/MAPKs pathway.  
 
5.9  Limitations 
This study has several limitations. I only used inhibitor experiments to 
characterise the pathway involved. Furthermore I used a relative high 
parthenolide concentration. But within 3 hours, there is no cytotoxic effect as 
shown by O`Neill et al. (O'Neill, Barrett et al. 1987). I also used high CT-1 
concentrations compared to concentrations reported in patients with CHF by Ng 
et al. (Ng, O'Brien et al. 2002). On the other hand a paper published in 2008 
(Natal, Fortuno et al. 2008) reported serum CT-1 concentration in healthy 
controls and patients with metabolic syndrome of about 100 ng/ml. So far, serum 
concentration of CT-1 in healthy controls and patients are a matter of discussion. 
However, independent of reported CT-1 serum concentration the concentration 
of CT-1 should be much higher in the myocardium which is the source of CT-1 in 
CHF (Asai, Saito et al. 2000). Exact intramyocardial CT-1 concentrations are not 
determined so far, only mRNA and immunhistochemical studies showed 
increased expression of CT-1 in hearts of patients with CHF (Zolk, Ng et al. 
2002). 
 
 
 
 
 
 
 
 
Conclusions 
6 Conclusions 
In conclusion, this study showed that both subunits for forming the heterodimer 
receptor of gp130/LIFR-β for CT-1 action were expressed on PBMC. Via this 
receptor, CT-1 activated PBMC by evoking ERK and P38 MAKP signaling 
pathways, and promoting TNF-α expression. CT-1 significantly induced TNF-α 
production at both mRNA and protein levels in PBMC. Moreover, it has been 
shown that the subpopulation of monocytes but not lymphocytes were 
responsible for this effect. I further found out that CT-1 can induce NFκB 
translocation into the nucleus in PBMC, which was mediated by IκB degradation. 
Parthenolide (an inhibitor of NFκB activation) interrupted nuclear translocation of 
NFκB and completely inhibited the CT-1-induced TNF-α expression in PBMC, 
whereas SB203580 (an inhibitor of P38 MAPK activation) and PD98059 (an 
inhibitor of ERK activation) had no effects on them. These results indicate that 
NFκB nuclear translocation is essential for CT-1-induced TNF-α expression in 
PBMC and that CT-1 might activate NFkB via Raf-1 directly as ‘‘skip’’ activation 
sequences but not via Raf-1/MEK/MAPKs pathway. 
These observations offer a new mechanism of activated PBMC, increased 
serum TNF-α concentration and active NFkB signaling pathway in CHF, which 
have significant implications for revealing a new mechanism of immune 
activation in CHF. Interestingly, in the present study LPS was not needed for the 
induction of TNF-α expression in PBMC. Moreover, this study may also elucidate 
a potential role of CT-1 in the pathophysiology of CHF and illustrate that heart is 
not only just a target of the inflammatory state in heart failure, but also play a role 
in the activation of inflammatory response by secreting CT-1 into the peripheral 
circulation, at least in part as a cause for initiating or promoting the inflammatory 
response in heart failure. In the light of these results, modulating CT-1 may be an 
interesting pharmacological target in the treatment of CHF. 
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